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List of abbreviations: 
Amp  amplicon 
bp  base pairs 
cDNA  complementary deoxyribonucleic acid 
ddH2O  double-distilled water 
DAA  direct acting antiviral  
DNA  deoxyribonucleic acid 
E.coli  Escherichia coli 
f  femto = 10-15 
fw  forward 
HCV  hepatitis C virus 
HIV  human immunodeficiency virus 
IFN  interferon 
IFN-alpha interferon-alpha 
kb  kilobases 
m  milli = 10-3 
MPC  Magnetic Particle Collector 
µ  micro = 10-6 
n  nano = 10-9 
NS2/3  non-structural protein 2/3 
NS5b  non-structural protein 5b 
p  pico = 10-12 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PTP  Pico Titer Plate 
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pIFN-alpha pegylated interferon alpha 
qPCR  quantitative polymerase chain reaction 
R2  square of the correlation coefficient R 
RAV  resistance associated variant 
RBV  ribavirin 
rev  reverse 
RNA   ribonucleic acid 
rpm  revolutions per minute 
RT  reverse transcription 
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I Introduction 
I.1 Hepatitis C 
The hepatitis C virus (HCV) is a 9.6 kb positive-sense, single-stranded RNA virus of the 
Flaviviridae family. Its genome “encodes a long polyprotein of more than 3000 amino acids that 
is proteolytically processed to generate 10 mature viral proteins” [1]. Viral structural proteins 
(core, E1, and E2) are encoded by the N-terminal part of the polyprotein. Viroporin p7 and non-
structural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) encode for enzymes like a serine 
protease, RNA helicase and the RNA dependent RNA polymerase as well as assembly factors for 
the replication complex [2, 3]. 
6 HCV-genotypes (1 to 6) and approximately 100 subtypes (a to n) have been identified. 
Genotypes differ in at least 30% of their sequence and subtypes in about 20–25% [4]. Globally, 
genotype 1 is the most common one with 46%, followed by genotypes 3 (22%) and 2 (13%). The 
most common subtype is genotype 1b, responsible for 22% of all infections. In North America, 
Latin America and Europe, genotype 1 is dominant (62–71%), while in Asia genotype 3 is most 
prevalent (39%). Egypt excluded, where genotype 4 accounts for 93% of all infections, genotype 
1 is also predominant in North Africa and the Middle East (46%). Australia is dominated by 
genotype 1 (53%), followed by genotype 3 (39%) [5].  
With approximately 2–3% of the world’s population (more than 170 million people) chronically 
infected [1, 3], hepatitis C virus represents a worldwide health burden. While Germany belongs 
to one of the countries with a lower HCV-prevalence, the Robert-Koch-Institut (RKI) indicates on 
its website that, according to studies from 2008 to 2011, HCV-RNA could be identified in at least 
0.3% of the German population. However, the real prevalence might be higher because people 
with a higher risk for HCV infection (prisoners, drug users, immigrants) were underrepresented 
in the study [6]. About 75% of HCV-infections in adults go on to become chronic infections [4], 
leading to severe liver disease, including cirrhosis and hepatocellular carcinoma amongst other 
complications [1]. Compared to HCV monoinfected patients, HIV/HCV co-infected individuals 
show an accelerated disease progression and poor treatment response to pIFN-alpha and RBV 
[7, 8].  
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HIV and HCV share similar risk factors like the use of injection drugs, contact with infected blood 
as through needles or blood transplants and sex with an infected partner. But because the 
possibility of HCV transmission is much higher when exposed to infectious blood then during 
sexual contact, HIV-positive patients have a 8–35-fold higher chance (79–95%) of being co-
infected with HCV when they acquired their HIV infection from drug use and not from sexual 
exposures [9]. 
The Swiss HIV Cohort Study, investigating 6534 HIV-infected individuals from 1998 until 2011, 
found 33.3% of HIV infected patients who used injection drugs to be co-infected with hepatitis 
C. For the non-drug user, homo- and heterosexual groups the incidence rates were much lower 
(3.0% and 0.8%) [10]. 
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I.2 Therapy 
Early therapy of chronic hepatitis C used to only consist of interferon-alpha (IFN-alpha), before 
ribavirin (RBV) was added to the treatment. The sustained virological response (SVR), defined as 
undetectable HCV RNA levels (<50 IU/ml) 24 weeks after the cessation of treatment, was 
thereby increased to about 50%. In 2000 the introduction of pegylated interferon-alpha (pIFN-
alpha), with a longer half-life, provided the advantage of weekly administration [11]. 
In 2011, the first two direct acting antivirals (DAAs), telaprevir and boceprevir were introduced 
into clinical practice. When combined with pIFN-alpha and RBV, these two protease-inhibitors 
helped to increase SVR rates by about 30% in treatment-naïve, and 26–60% in treatment-
experienced patients infected with genotype 1 [11]. 
Simeprevir and other second or third generation NS3/4A inhibitors show less side effects and a 
higher barrier to resistance [11]. Thanks to its 40h half-life, simeprevir needs to be administered 
only once a day. It is well tolerated, but typically causes asymptomatic high bilirubin levels [11]. 
Sofosbuvir, a NS5b polymerase inhibitor promises high SVR rates after 24 weeks of treatment 
for patients infected with genotype 1, 2 and 3, as monotherapy over 12 weeks or when 
combined with RBV and pIFN-alpha. Common adverse drug events are headache, fatigue, rash, 
and anemia amongst others [12]. 
The development of DAAs has “opened a new era to the possibility of IFN-free therapy, lower 
pill-burden, increased treatment success rate, as well as reduced duration of therapy” [13]. 
Severe IFN side-effects such as flu-like symptoms and anemia can even be avoided by an IFN-
free regimen like the combination of only the two DAAs simeprevir and sofosbuvir, as 
investigated by the COSMOS-study [14], where SVR rates after 12 weeks were found to be 92% 
in all patients. Minor adverse events found were fatigue, headache and nausea. Serious adverse 
events had only been seen in 2% of the patients, all of them treated with simeprevir and 
sofosbuvir only or in combination with RBV over 24 weeks. 
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Even without any prophylactic vaccine available [1], some clinicians optimistically “expect 
eradication of HCV on the earth within a few decades” [13]. On the other hand DAAs are very 
expensive, which limits the options on an interferon-free therapy for wide-spread use in all 
infected individuals, not only, but especially in developing countries [13]. Poor response rates in 
patients with liver cirrhosis and the emergence of resistance variants require a search for better 
therapies [1]. 
Pre-existing resistance-associated variants (RAV) and polymorphisms can be critical for 
treatment outcome, but usually are below viral sequence resolution limits [8]. However, with 
next generation sequencing like Roche’s 454 deep sequencing platform, extremely low 
percentages of variants in the genome can be detected, as low as 0.5–1%. 
Typical examples are polymorphisms at positions R155 and D168 in NS3A, associated with 
resistance against boceprevir, telaprevir, simeprevir and vaniprevir. S122A, S122R and S122G 
provide a certain resistance against simeprevir. Q80K and Q80R were found in less than 10% of 
treatment failure patients but provide 420-times and 305-times respectively the normal 
resistance compared to genotype 1b wild type replicon RNA when combined with R155K [15]. 
The highly variable polymorphism C316Y/N is located in NS5b and therefore associated with 
resistance against polymerase-inhibitors like sofosbuvir [16]. 
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I.3 Aim of the experiments 
I.3.1 Mutant Mix Experiment 
In preparation for the second experiment, deep sequencing of a mix of in vitro transcribed 
mutants S122R, R155K, D168V and a wild-type was conducted. To investigate the accuracy of 
deep sequencing especially at low percentages and low RNA input, these mutants were mixed 
together and the results were then compared back to the original percentages. Considering 
that, during treatment, viral loads can sometimes get very low in plasma from patients infected 
with HCV, the aim was to find a threshold for concentration of RNA at which deep sequencing 
results are still reliable. To mimic how cellular RNA might interfere with RNA extraction and 
reverse transcription of viral RNA in practice, RNA from Huh-7 Lunet cells was added as 
“background-RNA”. 
 
I.3.2 Plasma Samples Experiment 
For the second experiment, 16 plasma samples from treatment-naïve, HCV/HIV co-infected 
patients (11 genotype 1a and 5 genotype 1b samples) were screened for pre-existing variants in 
the NS3 and NS5b regions. Especially the two resistance-associated polymorphisms Q80K in NS3 
and C316N in NS5b were of interest. If commonly present in treatment-naïve patients, 
screening for these mutations before starting a highly expensive and maybe ineffective 
treatment with DAAs might be worth considering. 
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II Materials and methods 
II.1 Materials 
II.1.1 Consumables, chemicals, cell line 
Product Provider Specification 
96 well plate Greiner black 
Agarose BioShop Canada Inc. Cat. No: AGA 002.100 
Agencourt AMPure XP - PCR 
Purification  
Beckman Coulter A63880 
Lot: 14632800 
Ammonium acetate BioShop Canada Inc. 3M 
pH 7 
Ampicillin  BioShop Canada Inc.  
Bacteria  E.coli, strain: XL-1 
Genotype: recA1 endA1 gyrA96 
thi1 hsdR17 supE44 relA1 lac 
Cell line Dr. Ralf Bartenschlager Huh-7 Lunets 
Chloroform BioShop Canada Inc.  
Conical tube Falcon  
Diatec 8-strip PCR tube Diamed Product Code: 420-1375 
DNA dye Denville Scientific Inc. 
 
GreenGlo DNA dye  
Cat. No: CA3600 
DNA ladder  GeneDirex 100 bp 
H3 RTU (ready to use) 
With orange G tracking dye 
dNTP-Mix Thermo Scientific 10 mM each, 0,2 ml 
Cat. No: R0191 
Lot: 00196662 
Ethanol Commercial alcohols Cat. No: P016EAAN 
Lot 16404 
Flasks Sarstedt  
Gloves  
 
Kimberly-Clark 
 
REF 50706 
KC 300 
Sterling Nitrile Powder-free 
Glycogen   
Isopropyl alcohol 
 
BioShop Canada Inc. Cat. No: ISO920.4 
Lot: 4A32510 
Kimwipes disposable wipers  Kimberly-Clark Kimtech Science 
Lens cleaning wipes Zeiss Pre-moistened 
LB media BioShop Canada Inc.  
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Media Wisent Modified Eagles Media (DMEM) 
10% Fetal Bovine Serum (FBS) 
5% Penicillin 
5% Streptomycin 
5% Non-essential amino acids 
0.5 mg/ml G418 (Geneticin) 
Nucleoside Solutions Biobasic ATP, GTP, CTP, UTP 
PBS Wisent  
PCR tubes Eppendorf  
Phenochloroform BioShop Canada Inc.   
Phusion HF Buffer Thermo Scientific  Contains 7,5 mM MgCl2  
F-518Sx  
Lot: 00154037 
RNA ladder RiboRuler  High Range RNA Ladder 
Cat. No: SM1821 
RNA loading dye Thermo Scientific Fermentas 
2x RNA Loading dye 
Cat. No: R0641 
SOC Medium Solution BioShop Canada Inc. Cat. No: SOC 001.101 
10 ml 
Sparkleen solution Fisher Scientific Cat. No: 04-320-4 
Sterile disposable cell spreader Life Science Products Inc. Optimum 
Sodium Acetate BioShop Canada Inc. 3M 
pH 5.2 
TAE buffer BioShop Canada Inc. 1L TAE 50x = 242g Tris 
57,1 ml Glacid acetic acid 
100 ml of 0,5M ECTA pH 8.0 
Trypan Blue Solution Mediatech Inc. Cat. No. 25-900CI 
Trypsin Wisent  
Tween-20 Surfact-Amps 
Detergent Solution 
Thermo Scientific  
Water Thermo Scientific HyClone, HyPure Molecular 
Biology Grade Water 
Cat. No: SH30538.03 
Water EMD Millipore HPLC Grade 
Cat. No: WX0008-1 
Table 1: Consumables, chemicals, cell line. 
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II.1.2 Enzymes 
Enzyme Provider Specification 
DNA Polymerase 
And Buffer 
 
 Thermo Scientific PhusionTM High- 
Fidelity DNA Polymerase  
Cat. No: F-530S  
DNA Polymerase 
10x Pfu Buffer 
Agilent Cat. No: 600135 
 
Fast digest restriction enzymes 
Dpn1  
ScaI 
XhoI 
And 10x FD Buffer 
Thermo Scientific  
Cat. No: FD1703 
Cat. No: FD0434 
Cat. No: FD0694 
Green-2-Go-qPCR Mastermix Bio Basic Inc. Cat No: QPCR004-S 
Reverse Transcriptase and 
10x RT reaction buffer 
 
Agilent AccuScriptTM High Fidelity RT-
PCR Kit 
Cat. No: 600180 
TURBO DNase 
10x DNase Buffer 
Life Technologies TURBO DNA-free kit 
Cat. No: AM1907 
Table 2: Enzymes. 
II.1.3 Kits 
Kit Provider Specification 
Compact Prep Plasmid Midi Kit 
 
Qiagen Plasmid Midi Kit (25) 
Cat. No: 12843 
GS Junior emPCR kit (Lib-A) Roche Bead recovery reagents, 
emPCR reagents (Lib-A), 
Oil and Breaking Kit 
Cat. No: 05996520001 
GS Junior Sequencing Kit Roche Reagents and Enzymes, 
Buffers, 
Packing Beads and Supplement 
CB 
Cat. No: 05996554001 
GS Junior sipper maintenance kit Roche Cat. No: 07138857001 
GS Junior Titanium Control Bead 
Kit 
Roche Cat. No: 05996643001 
GS Junior Titanium PicoTiterPlate 
Kit 
Roche Cat. No: 05996619001 
PicoGreen Quant-iT dsDNA Assay 
Kit 
Invitrogen Cat. No: P7589 
 
RNA-extraction Kit (from plasma) Qiagen QIAmp Viral RNA Mini Kit 
Cat. No: 52904 
RNA-extraction Kit (from cells) Qiagen RNeasy Mini Kit 50 
Cat. No: 74104 
Table 3: Kits. 
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II.1.4 Laboratory equipment 
Device Provider Model 
Centrifuge Desaga Sarstedt-Gruppe M2 Cat. No. 185101 (Year 2004) 
Centrifuge Sigma Laboratory centrifuges  Model 6K 15 
Centrifuge Thermo Scientific Sorvall Legend RT Plus 
Cat. No: 75004377 
Gelbox Liberty2  
Biokey American Instruments 
Inc. 
High Speed/ bufferless/ 
conventional gel system 
Model: LBT2, Cat No: SYS-LBT2 
Serial No: 10444 
GS Junior 454 Bead counter Roche Cat. No: 06594662001 
GS Junior 454 BDD 
counterweight and adaptor 
Roche Cat. No: 05889103001 
GS Junior 454 Bead deposition 
device 
Roche Cat. No: 05996473001 
GS Junior 454 Sequencer Roche Cat. No: 05922160001 
Heat block (digital) VWR Cat. No: 12621-108 
Hemocytometer Assistent Germany  Improved Neubauer, bright-line 
0,1mm, Order No: 422/12 
Hood Nuaire Biological Safety Cabinet 
Model No: NU-425-400 
Hood Nuaire 
 
Biological Safety Cabinet 
Model No: NU-425-300 
Hood Ottawa Cabinet Company Ltd. Model number: CC475C 
Incubator Thermo Scientific Cat. No: 3110 
FormaTM Series II 3110 Water-
Jacketed CO2 Incubator 
Labquake shaker Lab Industries Inc. Cat No: 400-110 
Magnetic Particle Collector 
(MPC) 
Life Technologies 
Invitrogen 
DynaMagTM 2 Magnet 
Cat. No: 12321D 
Microscope Zeiss  
Nanodrop  Thermo Scientific Nanodrop2000 
Spectrophotometer 
Power supply Thermo Electron Corporation  Cat. No: 105ECA-LVD 
PCR machine Eppendorf Mastercycler gradient 
Real Time/qPCR machine  Biotech Inc. CR Corbett Research Model Rotor Gene 3000 
Spectra Max Microplate Reader Molecular Devices M5 
Tube disperser Roche IKA Ultra Turrax 
Cat. No: 05943353001 
Vacuum pump (oil free) Fisher Scientific Maxima Dry 
Type PU1308-N82.0-9.01 
Vortex Genie2 Scientific Industries Model G-560 
Cat. No: SI-0236 
Water bath Fisher Scientific  IsoTemp Digital Control Water 
bath Model 210 
Molecular Imager  Biorad  Gel Doc XR 
Table 4: Laboratory equipment. 
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II.1.5 Pipets and tips 
Device Provider Specification 
Barrier Tips MultiGuard 10, 100, 1000 µl 
Electronic Pipet Brand Handy Step 
Falcon serological pipet tips Fisher Scientific 2 ml 
Cat. No: 357507 
Low Binding Tips 
Next Generation Pipet Tip Refill 
System 
VWR 100, 200, 250 µl 
Cat. No: 89079-476 
Nunc Serological Pipet Thermo Scientific Inc. 50 ml disposable plastic pipet 
Cat. No: 170358 
PD-Tips Brand  
Progene Universal Fit Tips Ultident Scientific 1000 µl 
Cat. No: 87A1000 
Manual Pipets  Eppendorf  Research 10, 100, 1000 µl 
Serological pipet 
 
VWR 10 ml 
Cat No: 89130-898 
Tips 
Quick Rack Transfer System 
BioScience Inc. 0.1-10 µl graduated  
Cat. No: 30470 
Table 5: Pipets and tips. 
 
II.1.6 Plasma samples 
The plasma samples were drawn between 2008 and 2013, with the exception of one sample 
from 2003. 11 of the patient samples were genotype 1a and 5 were genotype 1b. All patients 
were treatment-naïve and HIV/HCV-co-infected. The viral load ranged between 573,382 and 
17,900,000 copies/ml. They were generously provided by a collaboration with Dr Marina Klein 
from McGill University Health Centre, Division of Infectious Diseases and Chronic Viral Illness 
Service.  
All plasma samples were shipped on dry ice and stored at -80°C. 
 
 
24 
 
 
      Table 6: List of plasma samples. 
 
II.1.7 Plasmids 
1a.US.77.H77 
HCV 1b 5.1 Replicon 
HCV NS3 in pET 21b 
 
II.1.8 Primers  
All deep sequencing primers used were full length HPLC purified. Chemical synthesis of primers 
starts at their 3’-end which may result in a truncated 5’-end in some cases. However, the 5’-end 
contains the important adapter sequence, key (TCAG) and Multiplex Identifier sequence (MID), 
which are important for binding to capture beads during emPCR and sequencing primers as well 
as identification of the amplicon during analysis. With an incomplete 5’-end, amplicons might 
not be detectable by deep sequencing. 
Deep sequencing primers are assembled: 
5’ – Adaptor sequence (fw/rev) – key – MID – template specific sequence – 3’ 
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Primer name Primer sequence 
Adaptor sequence fw (with key) 5’-CGTATCGCCTCCCTCGCGCCATCAG-3’ 
Adaptor sequence rev (with key) 5’-CTATGCGCCTTGCCAGCCCGCTCAG-3’ 
MID 1 5’-ACGAGTGCGT-3’ 
MID 2 5’-ACGCTCGACA-3’ 
MID 3 5’-AGACGCACTC-3‘ 
MID 4 5’-AGCACTGTAG-3‘ 
MID 5 5’-ATCAGACACG-3’ 
MID 6 5’-ATATCGCGAG-3’ 
MID 7 5’-CGTGTCTCTA-3’ 
MID 8 5’-CTCGCGTGTC-3’ 
MID 9 5’-TAGTATCAGC-3‘ 
MID 10 5’-TCTCTATGCG-3’ 
Template specific sequences: 
NS3p Amp7 fw 5‘-TGTAGACCAAGACCTCGTCG-3‘ 
NS3p Amp7 rev 5‘-GTGGGCCACCTGGAAT-3‘ 
NS3p Amp9 fw 5’-GTGACATCATCAACGGCTTG-3’ 
NS3p Amp9 rev 5’-TGCCTCGTGACCAGGTAA-3’ 
NS5b C316 Amp fw 5’-ACCCGCTGTTTTGACTCAAC-3’ 
NS5b C316 Amp rev 5’-GATGTTATCAGCTCCAAGTCGT-3’ 
S122R fw 5’-GCCGGCGGGGCGACCGCAGGGGGAGCCTACTCTCC-3’ 
S122R rev 5’-GGAGAGTAGGCTCCCCCTGCGGTCGCCCCGCCGGC-3’ 
   Table 7: Primer assembly. 
 
II.1.9 Software 
Software Provider 
GS Junior Amplicon Variant 
Analyzer 3.0 
Roche 
GS Junior Run Browser 3.0 Roche 
GS Junior Sequencer 454 Roche 
SoftMaxPro 5.2 Molecular Devices 
Rotorgene analysis software 
6.1.93  
Corbett Research 
  Table 8: Software. 
 
 
 
Random Hexamer Primer Thermo Scientific 120 µl, 100 µM Cat. No: S0142 
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II.2 Methods 
II.2.1 Deep sequencing work flow 
For both experiments, 454 GS Junior deep sequencing system was used. 
Deep sequencing work flow consists of three major steps: Amplicon library preparation, 
emulsion based clonal amplification (emPCR) and sequencing.  
RNA has to be converted into single stranded cDNA. Using PCR, double stranded DNA amplicons 
are amplified using primers specifically designed for the deep sequencing protocol. Amplicons 
then have to be cleared from any short by-products like primer-dimers and any remaining 
primer by using AMPure magnetic beads and a Magnetic Particle Collector (MPC). After 
purification, only highly pure PCR product eluted in TE buffer is left. The presence of by-
products in a library can be tested for by carrying out a quality control PCR (QCPCR). Amplified 
short products show up as secondary bands when run on an electrophoresis gel. Additionally, 
purity can be tested with the help of the Agilent 2001 Bioanalyzer. The library needs to be 
quantified fluorometrically using Quant-it Picogreen dsDNA Assay Kit. Based on the results, the 
concentration of each amplicon can be calculated and amplicons can then be diluted to a 
uniform concentration and pooled so that for the emPCR a certain number of molecules of 
library DNA per capture bead are added. 
For the emPCR, DNA template and special capture beads are mixed in an emulsion of water and 
oil, every water droplet ideally containing only one capture bead and one DNA template. During 
the following PCR, the DNA amplicon gets amplified while being attached to the adaptor on the 
bead until every capture bead contains millions of clonal copies. Afterwards, the emulsion has 
to be broken and treated with “melt solution” to leave PCR products single stranded. In the end 
as not all water droplets with a DNA capture bead will contain a DNA template, only DNA-
containing capture beads are to be kept. This step is called “enrichment”. 
After adding special sequencing primers, between 500,000 and 2 million enriched beads are 
loaded on the Pico Titer Plate (PTP). With the help of GS Junior bead counter, the percentage of 
enrichment can be estimated. The PTP device consists of hundreds of thousands of microscopic 
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wells. Every well contains ideally one Capture Bead with DNA. Additionally, three other layers of 
reagents (enzymes, packing beads, PPiase beads) are loaded onto the plate. During sequencing 
nucleotides (TACG) flow across the surface of the PTP one at a time for 200 cycles. With every 
nucleotide binding to DNA on the Capture Beads a chemiluminescent signal is generated, 
registered by a 6 megapixel CCD camera. With more than 50,000 reads obtained in parallel, 
deep sequencing gives detailed information on nature and quantity of sequence variants in the 
amplicon library. 
 
 
II.2.2 Mutant Mix Experiment 
II.2.2.1 Mutagenesis 
The in vitro transcribed mutants D168V and R155K were already present at the lab from 
previous experiments. For the Mutant Mix Experiment the mutant S122R was created and then 
transcribed into RNA. A HCV 1b 5.1 Replicon plasmid, 10x pfu Buffer and DNA Polymerase by 
Agilent were used. 
On ice, the following reagents were mixed together three times: 
Volume (µl) Reagent Concentration 
18,2 ddH2O   
2,5 Buffer (pfu) 10x 
0,625 dNTP Mix 10 mM 
1,25 Primer Forward 10 µM   S122R 
1,25 Primer Reverse 10 µM   S122R 
0,58 5.1 Replicon Plasmid 17.3 µg/µl 
0,6 DNA Polymerase (pfu) 25 units/µl 
total: 25 
      Table 9: Master Mix Mutagenesis. 
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A PCR was then conducted according to the following protocol, using a different annealing 
temperature for each of the three tubes (51.0°C, 52.5°C, 56.5°C): 
 
PCR Program Temperature Time   
Step 1 Initial Denaturation 95°C 2 min 
35 cycles 
Step 2 Denaturation 95°C 30 sec 
Step 3 Annealing 
51.0°C  
30 sec 52.5°C 
56.5°C 
Step 4 Extension 72°C 5.5 min 
Step 5 Hold 4°C 
     Table 10: Amplicon PCR protocol Mutagenesis. 
 
0.6 µl of Dpn1 was added to the 3 PCR products. Tubes were put in a heat block at 37°C and left 
1h to digest. 90 µl of E.coli from a glycerol stock at -80°C were slowly thawed on ice. By the 
flame, 3 µl of PCR product and 30 µl of bacteria were pipetted into sterile 1.7 ml tubes. Tubes 
were stored on ice for 30 minutes, then heat shocked at 42°C for 45 seconds. 200 µl of SOC 
medium solution was added using sterile pipet tips (autoclaved). Tubes were incubated in a lab 
shaker for 20 minutes at 37°C. By the flame of a Bunsen burner, liquid was poured from the 
three tubes into three plates with ampicillin and distributed with a sterile spreader. Plates were 
incubated upside down at 37°C overnight. 
Working by the flame: The next day, a 15 ml conical tube was filled with 4.5 ml LB media and 10 
µl Ampicillin. One single colony per plate was picked with a sterile pipet and transferred into the 
15 ml tube, which was then incubated in a lab shaker at 37°C overnight. 
The next day, bacteria were mini-prepped using Qiagen Compact Prep Plasmid Midi kit, 
following its manual. 
Mini-prep products were nanodropped and then stored at -20°C until further proceeding. 
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II.2.2.2 Digestion 
4 µl of FD Buffer, 1 µl of each the restriction enzymes XhoI and ScaI were added to 26 µl of DNA 
S122R (at a concentration of 115 ng/µl) and mixed with 8 µl of RNase-free water. The contents 
(40 µl total) were incubated for 2 hours at 37°C. With RNase-free water, the mix was brought up 
to a volume of 200 µl before 300 µl of Phenochloroform were added. After mixing carefully, the 
tube was centrifuged for 5 minutes at approximately 13,000 rpm. The upper layer (150 µl) was 
extracted and added to 300 µl of chloroform. After mixing, the tube was spun for 5 minutes in a 
bench centrifuge. The upper layer was extracted and added to 600 µl of 100% ethanol, 20 µl of 3 
M Sodium Acetate at a pH of 5.2 and 0.5 µl of Glycogen at a concentration of 20 mg/ml. The 
mixture was stored at -20°C overnight. 
On the next day, the tube was centrifuged at 4°C for 1 hour at 13000 rpm.  Supernatant was 
removed and 300 µl of 70% ethanol were added. After spinning it again at 4°C for 1 hour for 
13000 rpm, supernatant was again removed and 300 µl of 100% ethanol were added. After 
spinning it for a third time at 4°C for 1 hour at 13000 rpm, supernatant was removed and DNA 
was left to air dry for 10 minutes. DNA was resuspended in 42 µl of RNase-free water. 2 µl were 
then used to determine its concentration with the help of nanodrop. 
 
II.2.2.3 In vitro transcription 
In a 1.7 ml Eppendorf tube, 8 µl of linear DNA (0.8 µg), 2 µl of each ATP, CTP, GTP and UTP 
solution and 2 µl of enzyme mix and 2 µl of 10x reaction buffer were mixed by pipetting up and 
down several times. The tube was incubated at 37°C for 4 hours. Afterwards, 1 µl of TURBO 
DNase was added, contents were mixed and then incubated at 37°C for 15 minutes. 115 µl of 
RNase-free water and 15 µl of Ammonium acetate (3M, pH7) were added, along with 300µl of 
Phenol Chloroform. After spinning at 4°C for 10 minutes, 300 µl of chloroform were added. The 
tube was again centrifuged at 4°C for 10 minutes. After that, the top layer was transferred to a 
new 1.7ml tube with 400 µl of isopropanol. The new tube was stored at -20°C overnight. 
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On the next day, the mix was centrifuged at 4°C for 1 hour. Supernatant was removed. 300 µl of 
70% ethanol were added. After spinning for a second time at 4°C for 1 hour, supernatant was 
removed and 300 µl of 100% ethanol were added. The tube was spun a third time at 4°C for 1 
hour and the supernatant was again taken out and discarded. After letting it air dry for 10 
minutes, RNA was resuspended in 50 µl of RNase-free water and nanodropped to find its 
concentration. 
 
II.2.2.4 Start of new cell line 
A new cell line of Huh-7 Lunets was started (cells from stock frozen with liquid nitrogen). 
Huh-7 Lunet cells from a liquid nitrogen stock were slowly thawed on ice, and then defrosted in 
a 37°C water bath. The tube was flicked several times. The cells were then put in 10 ml warm 
media in a 15 ml falcon tube and mixed by pipetting up and down 2-3 times. The tube was 
centrifuged for 5 minutes at 3600 rpm at room temperature. The media was removed and 
replaced by 10 ml fresh media. Cells were mixed by pipetting up and down several times. The 
whole content was added to a 20 ml flask. 5 ml of media were added and the flask was kept at 
37°C overnight. On the next day, old media was removed and replaced by 15 ml of fresh media. 
3 days later cells appeared to be about 75-80% confluent, so they were split: Old media was 
removed from the flask and discarded. 10 ml sterile PBS were used to wash the bottom of the 
flask, then removed and discarded. 3 ml of trypsin were added and the flask was moved around 
so that trypsin covered the entire bottom of the flask. Trypsin was then removed and the flask 
was incubated at 37°C for 5 min. Only 1/6 of the cells was kept, by adding 6ml of media to the 
cells, pipetting up and down and then adding the 6 ml media plus cells to a 15 ml falcon tube. 1 
ml of this was put back in the flask, together with 14 ml of fresh media. 
 
 
 
31 
 
II.2.2.5 Cell harvesting and cell counting  
7 days after starting the new cell line, supernatant was harvested. Old media was removed from 
the flask, cells were washed with sterile PBS, then treated with trypsin and incubated at 37°C for 
5min. 6 ml of media was added to the flask, cells and media were mixed well by pipetting up 
and down and then transferred to a 15 ml falcon tube. 
10 µl of cells were added to an Eppendorf tube with 90 µl of trypan blue and mixed. 10 µl of this 
mixture was placed on the grid of a hemocytometer and cells were counted under a 
microscope. Cells in 4 squares (0.2 x 0.2mm) of the counting chamber, each consisting of 16 
small squares (0.05 x 0.05mm) were counted and the mean value was calculated. The calculated 
number of cells times 10,000 equals the number of cells per µl in the falcon tube. As 6 ml of 
media had been transferred into the falcon tube, the number of cells per µl times 6000 equals 
the total number of cells. For the RNA extraction, 105 to 106 cells were needed. 
In the meantime, the remaining 6 ml of cells and media were spun at 1000 rpm. Supernatant 
was removed and cells were resuspended in 10 ml sterile PBS and again spun at 1000 rpm. 
Supernatant was removed and the remaining cells were used for a RNA extraction. 
 
II.2.2.6 RNA extraction  
RNA was extracted with RNeasy Mini Kit from Qiagen, following its manual RNeasy Mini 
Handbook June (2012) [17]. 
RNA was then nanodropped to determine its concentration and stored at -80°C until further 
proceeding.  
 
 
 
32 
 
II.2.2.7 Mix at RNA level 
A mix, containing 85% of WT RNA (plasmid pET in 21b), 12%, 2.7% and 0.3% of the in vitro 
transcribed mutants S122R, R155K and D168V was created (see table 11). 
 
RNA Mix 
WT 85% 
S122R 12% 
R155K 2.7% 
D168V 0.3% 
           Table 11: Original concentrations of the RNA mutants. 
 
In order to have a RNA mix with a final concentration of 5ng/µl, 4 samples at 100ng/µl each 
were used. 4.25 µl of the WT RNA, 0.6 µl of the S122R mutant, 1.35 µl of a 1/10 dilution of the 
R155K mutant and 1.5 µl of a 1/100 dilution of the D168V mutant were mixed together. These 
first 7.7 µl contained 500 ng of RNA mix. 92.3 µl of RNase-free water was added in order to have 
100 µl of a final concentration of 5ng/µl (see figure 1). 
 
 
  Figure 1: Calculation of the amounts of mutant RNA to be added to the Mutant Mix. 
 
 
This RNA mix at a concentration of 5
1/10,000 and 1/100,000 to get final concentrations of 
50 fg/µl (see figure 2). 
                 Figure 2: Serial dilution of the RNA 
 
 
II.2.2.8 Reverse Transcription 
A reverse transcription of each dilution of the RNA mix (5
pg/µl and 50 fg/µl) was conducted according to the following proto
Additionally, a reverse transcription of 
following the same protocol. 
In order to simulate the RNA background 
extraction and reverse transcription of 
harvested RNA from Huh-7 Lunet cells
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 ng/µl was then further diluted 
0.5 ng/µl, 50 pg/µl, 5
Mutant Mix. 
 ng/µl, 0.5 ng/µl
col (see tables 12, 13
the WT plasmid pET in 21b (78 
coming from cellular RNA that might
viral RNA from human plasma, 
 was added to the reaction. 
 
1/10, 1/100, 1/1000, 
 pg/µl, 0.5 pg/µl and 
 
, 50 pg/µl, 5 pg/µl, 0.5 
). 
ng/µl) was conducted 
 interfere with the 
a total of 998.3 ng of 
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Volume (µl) Reagent Concentration 
8.51 ddH2O   
2 AccuScript RT Buffer   
1 Random Primer   
2 dNTP 10mM 
1.49 RNA background from cells 670 ng/µl 
1 
Mutant Mix RNA 5ng, 0.5ng,   
50pg, 5pg, 0,5pg,   
50fg 
WT plasmid pET in 21   
total: 16.5 
    Table 12: Master Mix Reverse transcription Mutant Mix Experiment. 
 
The mix was incubated at 65°C for 5 minutes, then briefly cooled at room temperature for 5 
minutes. The following components were added to the reaction mix: 
 
Volume (µL) Reagents Concentration 
2 DTT 100 mM 
1 Accuscript RT 40 U/µl 
0.5 Rnase Inhibitor   
Table 13: Master Mix 2 Reverse transcription Mutant Mix Experiment. 
 
The following program was run: 
 
  Temperature Time 
Preheat 25°C 10 min 
  42°C 60 min 
  70°C 10 min 
Hold 4°C   
  Table 14: Reverse transcription protocol Mutant Mix Experiment. 
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II.2.2.9 Primer optimization (primer tests) NS3p Amp7 MID1 
Mutants S122R, R155K and D168V are located in the protease region of NS3. The amplicon 
covering all three mutants was named NS3p Amp7.  
The primers NS3p Amp7 MIDx forward and reverse were already at the lab from previous 
experiments. Primers generating amplicons for deep sequencing have to be very exact, leaving 
no short by-products such as free adaptors and adaptor dimers, as those can later interfere with 
the emPCR by binding to capture beads amongst other reasons. Therefore, they were tested on 
a HCV 1b 5.1 Replicon plasmid. First a concentration gradient, then in a second reaction a 
temperature gradient was tested and the products were run on a 1.5% agarose electrophoresis 
gel (as described in section II.2.2.12), in order to look for secondary bands showing short 
products. Temperature and concentration showing the best conditions (clear band, no faint 
secondary bands) were used for further experiments. 
A concentration gradient of the primer was created by making a serial diluting of each forward 
and reverse primer, starting from 10 µM and 5 times diluting one in two (see figure 3). 
 
              Figure 3: Concentration gradient for primer tests. 
For the temperature gradient, annealing temperatures 51.0°C, 52.5°C, 54.2°C, 56.5°C, 59.1°C, 
61.8°C and 64.5°C were used. 
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Tables 15 and 16 show the protocol for the concentration gradient reaction, tables 17 and 18 
for the temperature gradient reaction. 
 
Volume (µl) Reagent Concentration 
13.8 ddH2O   
5 Buffer   
0.5 dNTP Mix 10 mM 
2.5 Primer Forward 10 µM   NS3p Amp7 MID1 
2.5 Primer Reverse 10 µM   NS3p Amp7 MID1 
0.15 
HCV 5.1 1b Replicon 
plasmid 33.2 ng/µl 
0.5 DNA Polymerase (phusion) 2 units/µl 
total: 25 
 Table 15: Master Mix primer test NS3p Amp7 MID1 concentration gradient. 
 
PCR Program Temperature Time   
Step 1 Initial Denaturation 98°C 30 sec 
30 cycles 
Step 2 Denaturation 98°C 10 sec 
Step 3 Annealing 64.5°C 30 
Step 4 Extension 72°C 15 sec 
Step 5 Extension 72°C 7 min 
Step 6 Hold 4°C 
     Table 16: PCR program primer test NS3p Amp7 MID 1 concentration gradient. 
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Volume (µl) Reagent Concentration 
17.6 ddH2O   
5 Buffer   
0.5 dNTP Mix 10 mM 
0.625 Primer Forward 10 µM   NS3p Amp7 MID1 
0.625 Primer Reverse 10 µM   NS3p Amp7 MID1 
0.15 
HCV 5.1 1b Replicon 
plasmid 33.2 ng/µl 
0.5 DNA Polymerase (phusion) 2 units/µl 
total: 25 
  Table 17: Master Mix primer test NS3p Amp7 MID1 temperature gradient. 
 
PCR Program Temperature Time   
Step 1 Initial Denaturation 98°C 30 sec 
30 cycles 
Step 2 Denaturation 98°C 10 sec 
Step 3 Annealing 
51.0°C 
30 sec 
52.5°C 
54.2°C 
56.5°C 
59.1°C 
61.8°C 
64.5°C 
Step 4 Extension 72°C 15 sec 
Step 5 Extension 72°C 7 min 
Step 6 Hold 4°C 
     Table 18: PCR program primer test NS3p Amp7 MID 1 temperature gradient. 
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II.2.2.10 qPCR 
To quantify the cDNA after the reverse transcription, a Real Time quantitative PCR (qPCR) was 
conducted, according to the following protocol (see table 19). The reaction consisted of 40 
cycles. NS3p Amp7 (without MID) was used as primer. 
Reagent Volume (µl) 
Green-2-go 
Mastermix 10   
Forward Primer 
10uM 1   
Reverse Primer 10 
µM 1   
PCR Water 7   
Template 1     
Total 20   
qPCR Program 
        
  
Temperature 
(ºC) Time   
Hold 95 10 min   
Place 
# Description Conc. unit 
Cycling 95 30 sec   1 
Standard                               
HCV1b Neo WT 
1.5625 ng/µl 
  59 60 sec   2 0.78125 ng/µl 
  72 90 sec   3 0.390625 ng/µl 
Melt 72 - 95       4 0.195313 ng/µl 
Rising 1 degree each step   5 0.097656 ng/µl 
45 second wait after 1st step   6 0.048828 ng/µl 
Then 5 second wait after each step afterwards   7 0.024414 ng/µl 
8 0.012207 ng/µl 
9 0.006104 ng/µl 
10 0.003052 ng/µl 
11 0.001526 ng/µl 
12 0.000763 ng/µl 
 
 
13 0.000381 ng/µl 
14 0.000191 ng/µl 
15 Blank 
    
16 Mutant Mix 5 ng/µl 
    
17 Mutant Mix 0.5 ng/µl 
    
18 Mutant Mix 50 pg/µl 
    
19 Mutant Mix 5 pg/µl 
    
20 Mutant Mix 0.5 pg/µl 
    
21 Mutant Mix 50 fg/µl 
    
22 HCV 1b WT control     
Table 19: qPCR protocol Mutant Mix Experiment. 
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II.2.2.11 Amplicon PCR 
An amplicon PCR was conducted on the 6 reverse transcription products according to the 
following protocol (see tables 21, 22). 0.2 ml tubes were used. The annealing temperature was 
52.5°C. 
NS3p Amp7 MIDx was used as primer. For each dilution of the mutant mix, a different MID was 
used (see table 20). The final concentration of primer in the reaction mix was 0.25 µM. 
As a positive control served the plasmid WT NS3 in pET 21b from the reverse transcription, and 
one PCR containing only RNase-free water instead of cDNA served as negative control.  
 
 
             Table 20: Assignment of MIDs to Mutant Mix dilutions. 
 
Volume (µl) Reagent Concentration 
34 ddH2O   
10 Buffer   
1 dNTP Mix 10 mM 
1.25 Primer Forward 10 µM   NS3p Amp7 MIDx 
1.25 Primer Reverse 10 µM   NS3p Amp7 MIDx 
2 cDNA   
0.5 DNA Polymerase (phusion) 2 units/µl 
total: 50 
  Table 21: Master Mix Mutant Mix cDNA. 
 
cDNA MID 
5 ng/µl MID 1 
0.5 ng/µl MID 2 
50 pg/µl MID 3 
5 pg/µl MID 4 
0.5 pg/µl MID 5 
50 fg/µl MID 6 
WT control MID 6 
Negative control MID 1 
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PCR Program Temperature Time   
Step 1 Initial Denaturation 98°C 30 sec 
30 cycles Step 2 Denaturation 98°C 10 sec Step 3 Annealing 52.2°C 30 sec 
Step 4 Extension 72°C 15 sec 
Step 5 Extension 72°C 7 min 
Step 6 Hold 4°C 
     Table 22: PCR protocol Mutant Mix cDNA. 
 
II.2.2.12 Run on 1.5% agarose gel 
Amplicons of the 6 dilutions of the Mutant Mix (5 ng, 0.5 ng, 50 pg, 5 pg, 0.5 pg and 50 fg), the 
positive control (WT from pET in 21b plasmid) and the negative control were run on a 1.5% 
agarose gel for approximately 30–40 minutes at 130V and 60–80A, along with a 100bp DNA 
ladder as follows: 
1.5 g of agarose were melted in 100 ml TAE buffer by heating it up in a microwave for 2 
minutes. When cooled down to approximately 55°C, 10 µl of Greenglo DNA dye were added. 
Afterwards the liquid was poured into a gelbox with a comb and left to dry. Once dried, the 
comb was removed. At the cathode and anode ends of the box the chambers were filled with 
TAE buffer. The middle chamber containing the gel was filled up with RNase-free water. Before 
loading 5 µl the samples into the wells of the dried gel, they were mixed with 1 µl of orange G 
tracking dye. 5 µl of the 100 bp DNA ladder were loaded next to the samples. A picture of the 
gel was taken with gel doc system by biorad. 
 
II.2.2.13 Library Purification 
Purification was conducted according to GS Junior Amplicon Library Preparation Method 
Manual (March 2012) [18] section 3.2.2 for PCR tubes: 
At first, 22.5 µl of molecular biology grade water were pipetted into 1.5 ml tubes (one per 
amplicon). Then, 22.5 µl of each PCR product was added to each 1.5 ml tube. Into each tube, 
72.0 µl of AMPure beads were transferred and then mixed by vortexing for 5 seconds. Tubes 
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were incubated for 10 minutes at room temperature and then placed in a Magnetic Particle 
Collector (MPC) where they were again incubated for 5 minutes at room temperature. With the 
tubes still in the MPC, the supernatant was removed and discarded without disturbing the 
beads. Then, 200 µl of 70% ethanol (freshly prepared) were added to each tube and mixed by 
vortexing for 5 seconds. Tubes were put back in the MPC and incubated for 1 minute at room 
temperature. With the tubes still in the MPC, supernatant was again removed and discarded 
without disturbing the beads. The wash with 70% ethanol was repeated. Open tubes were then 
placed on a heatblock at 37°C until the pellet had dried sufficiently (not longer than 5 minutes 
to avoid overdrying). 10 µl of 1xTE was added to each tube and mixed by vortexing. Tubes were 
placed in the MPC and incubated for 2 minutes at room temperature. With the tubes still in the 
MPC, supernatant was transferred to new screw cap o-ring 1.5 ml tubes. Purified amplicons 
were stored at -20°C until further proceeding. 
 
II.2.2.14 Library quality control PCR (QCPCR) 
A library quality control PCR was conducted according to section 3.3 of the GS Junior Amplicon 
Library Preparation Method Manual (March 2012) [18]. For each amplicon to be tested, the 
following mix was prepared (see table 23): 
 
Reagent Volume 
Molecular Biology Grade Water 39 µl 
PCR Buffer 10x 5 µl 
dNTP mix (10mM each) 2 µl 
Forward Primer (10µM) 1 µl 
Reverse Primer (10µM) 1 µl 
Amplicon Library 
(2x10^8 molecules/µl, estimated) 
1 µl 
Polymerase  1 µl 
Total 50 µl 
               Table 23: QCPCR mix. 
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The PCR program was run according to the following table (see table 24): 
 
1x 94°C 11 min 
20x 94°C 1 min 
 60°C 1 min 
 72°C 1 min 
1x 72°C 10 min 
 At 4°C on hold  
 Table 24: QCPCR program. 
Samples were then run on a 1.5% agarose gel to amplify and detect any contaminating small 
PCR products (as described in section II.2.2.12). 
 
II.2.2.15 Bioanalyzer 
Additionally, quality control PCR products as well as purified amplicons were later sent to 
another lab to be run on Agilent 2100 Bioanalyzer system which is very sensitive in detecting 
contaminating short fragments. 
 
II.2.2.16 PicoGreen Quantification (Library quantitation) 
To quantify the library fluorometrically, Quant-it Picogreen dsDNA Assay Kit was used. As 
recommended in the GS Junior Amplicon Library Preparation Method Manual (March 2012) 
[18], the assay was carried out in duplicates (both samples and standard curve). 
Eight 1.5 ml tubes were labelled 1-8 and 1xTE was transferred into them as follows: 
Tube 1   594 µl 
Tubes 2-8  300 µl 
6 µl of DNA standard provided with the kit was transferred to tube 1 (1/100 dilution) and the 
tube was vortexed for 10 seconds. 300 µl were then transferred from tube 1 to tube 2, from 
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tube 2 to tube 3 and so on until tube 7, each time the tubes were vortexed for 10 seconds. Tube 
8 remains without DNA standard. 100 µl of each DNA standard dilution were transferred to the 
wells of a black fluorometer plate as follows (see table 25):  
row 1 2 3 4 
Line  Standard (amount of DNA) Amplicon DNA to measure 
A 100 ng 100 ng   
B 50 ng 50 ng   
C 25 ng 25 ng   
D 12.5 ng 12.5 ng   
E 6.25 ng 6.25 ng   
F 3.13 ng 3.13 ng   
G 1.56 ng 1.56 ng   
H 0 ng 0 ng   
             Table 25: Black fluorometer plate. 
 
99 µl of 1x TE Buffer were transferred to the remaining wells (2 per amplicon). 1.0 µl of each 
purified amplicon DNA sample was transferred to the appropriate wells of the fluorometer 
plate. Samples were mixed by pipetting up and down 4 times with a multichannel pipet. 100 µl 
of a 1:200 dilution of PicoGreen reagent were added to each well. Samples and standards were 
mixed by pipetting up and down 4 times. The fluorescence was then measured with Spectra 
Max Microplate reader. 
Wavelengths: excitation ~ 480 nm, emission ~ 520 nm 
As all assays had been carried out in duplicates, each mean value was calculated by adding both 
values and dividing them by two. Then, the fluorescence value of the reagent blank was 
subtracted from that of each of the samples. A standard curve was created by plotting the 
fluorescence emission intensity versus DNA concentration. 
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II.2.2.17 Amplicon dilution and pooling 
Based on the PicoGreen results, the concentration of each amplicon was calculated as follows, 
according to GS Junior Amplicon Library Preparation Method Manual (March 2012) [18]: 
Molecules/µl = [sample conc (ng/µl) * 6.022x1023] / [656.6x109 * amplicon length (bp)].  
Amplicons were then separately diluted down to 109 molecules per µl in 1x TE buffer by adding 
1 µl in the volume of TE buffer calculated using the following formula: 
{[Molecules/µl (from Step 1) / 109] -1} µl. 
The amplicons were then pooled by mixing together 10 µL of each of the dilutions. The pooled 
samples were further diluted to 107 molecules per µl by adding 2 µl of the amplicon pool to 198 
µL of Molecular Biology Grade Water.  
The GS Junior Amplicon Library Preparation Method Manual (March 2012) [18] recommends an 
input of 2 molecules of Library DNA per capture bead. The volume of DNA library needed can be 
calculated using the following formula: 
µl of DNA library per tube = (Desired molecules per bead * 10 million beads) / (library 
concentration in molecules/µl). 
A volume between 5 µL and 30 µL has to be added during emPCR in the end. Depending on 
these numbers and the concentrations, all samples had to be diluted further down to 2x105 
molecules per µl. 
Pooled amplicons were stored at -20°C. 
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II.2.2.18 emPCR 
The emPCR was conducted according to GS Junior emPCR Amplification Method Manual Lib-A 
(May 2010) [19]: 
All kit components except for the Enzyme Mix and PPiase tubes which were kept at -20°C, were 
thawed at room temperature and then mixed by vortexing. The tube of Additive was thawed for 
5 minutes in a heat block at 55°C and then vortexed. 
The tube of emulsion oil was mixed for 10 seconds and then poured into the Turrax stirring 
tube. 1x Mock Mix was prepared by mixing 430 µl of Mock Mix with 1.72 ml of Molecular 
Biology Grade Water. Then, 2.0 ml of 1x Mock Mix was added to the emulsion oil in the Turrax 
stirring tube. The Ultra Turrax Tube Drive was set to 4000 rpm for 5 minutes and started. 
Two reaction mixes (Live Amp A and Live Amp B) were prepared according to tables 26 and 27 
and then stored on ice. 
Reagent Volume (µl) 
Molecular Biology Grade Water 205 
Additive 260 
Amp Mix 135 
Amp Primer B 40 
Enzyme Mix 35 
PPiase 1 
Total: 676 
     Table 26: Live Amp A. 
Reagent Volume (µl) 
Molecular Biology Grade Water 205 
Additive 260 
Amp Mix 135 
Amp Primer A 40 
Enzyme Mix 35 
PPiase 1 
Total: 676 
     Table 27: Live Amp B.  
1 ml of 1x Wash Buffer was added to both tubes of Capture Beads and vortexed. The Capture 
Beads were pelleted in a bench centrifuge by spinning, rotating, spinning. Supernatants were 
removed. Beads were once more washed with Wash Buffer. The volume of DNA library needed 
was calculated using the following formula: 
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µl of DNA library per tube = (Desired molecules per bead * 5 million beads) / (library 
concentration in molecules/µl). 
According to the manual, approximately 2 molecules of library DNA per Capture bead yields a 
bead enrichment between 5% and 20% (equals 500,000 to 2 million enriched beads). 
As the library DNA had been diluted to a concentration of 2x105 molecules/µl and the desired 
number of molecules per bead was 0.7 (due to previous experiences with similar experiments), 
17.5 µl of DNA library were added to each washed Capture Beads A and B. Both tubes were 
vortexed. To the tube of Capture Beads B, 600 µl of Live Amp Mix B were added. After 
vortexing, the entire content was added to the Turrax stirring tube. The Ultra Turrax Tube Drive 
was set to 2000rpm for 5 minutes and started to mix the emulsion.  
Afterwards, Live Amp Mix A was equally handled. 
100 µl of emulsion were aliquoted into nine 8-strip cap tubes, using HandyStep electronic pipet. 
A PCR was conducted according to the following program (see table 28): 
1x 4 minutes at 94°C 
50x 30 seconds at 94°C 
4.5 minutes at 58°C 
30 seconds at 68°C 
End 10°C on hold 
Table 28: emPCR program. 
 
II.2.2.19 Bead recovery and enrichment 
Bead recovery and enrichment were conducted according to GS Junior emPCR Amplification 
Method Manual Lib-A (May 2010) [19]: 
In an externally ventilated hood, the emulsion was aspirated from all wells of the strip tubes 
into a 50 ml conical tube, using a bench top vacuum system. Tubes were rinsed twice with 100 
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µl isopropanol per well. The rinse, as well as an additional approximately 5 ml isopropanol were 
added to the conical tube. 
For the following steps the conical tube was taken out of the ventilated hood. It was vortexed 
and 35 ml isopropanol were added before vortexing again. Beads were pelleted in a centrifuge 
at 930 x g for 5 minutes. Supernatant was discarded carefully. 10 ml of Enhancing Buffer were 
added and the tube was vortexed to resuspend the pellet. Isopropanol was added to a final 
volume of 40 ml and the tube was vortexed. Beads were pelleted in a centrifuge at 930 x g for 5 
minutes and again supernatant was poured out and discarded. For another wash, isopropanol 
was added to a final volume of 35 ml, the tube was vortexed and the beads then pelleted in a 
centrifuge at 930 x g for 5 minutes. Supernatant was removed. Finally, Enhancing Buffer was 
added up to a final volume of 35 ml, the tube was vortexed and spun in a centrifuge at 930 x g 
for 5 minutes. Supernatant was taken out, leaving approximately 2 ml of Enhancing Buffer in the 
tube. The DNA bead suspension was transferred into a 1.7 ml tube. After spinning, rotating, 
spinning the small tube, supernatant was discarded. The 50 ml tube was rinsed with 1 ml of 
Enhancing Buffer which was then added to the small tube. The tube was again spun, rotated, 
spun and supernatant was taken out. The bead pellet was rinsed twice with 1 ml of Enhancing 
Buffer, spun, rotated, spun both times and supernatant was discarded. 
1 ml of Melt Solution (125 µl of 10M NaOH in 9.875 ml of Molecular Biology Grade Water) was 
added to the 1.7 ml tube with DNA bead suspension. After incubating for 2 minutes at room 
temperature, the tube was vortexed, spun, rotated, spun and supernatant was discarded. The 
melt step was repeated once. 1 ml of Annealing Buffer was added. After vortexing, spinning, 
rotating, spinning the supernatant was taken out. The annealing step was repeated twice. 45 µl 
of Annealing Buffer and 25 µl of Enrichment Primer were added to the beads. The tube was 
vortexed and placed in a heat block at 65°C for 5 minutes and then promptly cooled on ice for 2 
minutes. 1 ml of Enhancing Buffer was added, the tube was vortexed, spun, rotated, spun and 
supernatant was discarded. The enhancing step was repeated twice. 1 ml of Enhancing Buffer 
was added, the tube was vortexed and set aside at room temperature until further proceeding. 
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A tube of brown Enrichment Beads from the kit was vortexed one minute to resuspend its 
contents completely. The tube was then placed for 3 minutes in a Magnetic Particle Collector 
(MPC) to collect the beads. After discarding the supernatant, 500 µl of Enhancing Buffer were 
added and the tube was vortexed. Beads were again pelleted using the MPC. Supernatant was 
taken out. The wash with 500 µl of Enhancing Buffer was repeated. After discarding the 
supernatant, 80 µl of Enhancing Buffer were added and the tube was vortexed. 
The 80 µl of brown Enrichment Beads in Enhancing Buffer were added to the 1.7 ml tube with 
DNA Bead Suspension. The mix was vortexed and then incubated for 5 minutes at room 
temperature on a lab rotator. Afterwards, the tube was placed for 4 minutes on the MPC. The 
MPC was inverted several times. The supernatant was carefully taken out, without touching the 
magnetic brown beads. The pellet was then washed several times (approximately 6 to 10 times) 
until no more white DNA beads were aspirated (supernatant was collected in extra tubes and 
spun in a centrifuge in order to make sure that no more white beads were left).The washes 
were conducted as follows: After adding 1 ml of Enhancing Buffer, the tube was vortexed and 
then placed in the MPC. Approximately 3 minutes later, supernatant was carefully taken out. 
To the tube of enriched beads, 700 µl of Melt Solution were added. After vortexing, the tube 
was placed in the MPC until the beads had pelleted. With the tube still on the MPC, the 
supernatant containing the enriched DNA beads was transferred to a new 1.7 ml tube. The 
brown beads were again treated with 700 µl Melt Solution and supernatant was added to the 
new tube.  To make sure that no brown beads had been aspirated with all the white beads, the 
new 1.7 ml tube was spun, rotated, spun in a bench top centrifuge. Supernatant was discarded. 
1 ml of Annealing Buffer was added and the tube was vortexed. After spinning, rotating, 
spinning the supernatant was taken out. The wash with Annealing Buffer was repeated twice. 
Finally, 100 µl of Annealing Buffer were added and the tube was vortexed.  
Then, 25 µl of Seq Primer from the kit was added, the tube was vortexed and then placed in a 
heat block at 65°C. After 5 minutes, the tube was promptly cooled on ice for 2 minutes. 
Afterwards, 1 ml of Annealing Buffer was added. After spinning, rotating, spinning the 
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supernatant was discarded. The wash with Annealing Buffer was repeated three times, but after 
spinning, rotating, spinning for the last time, supernatant was left in the tube. 
 
II.2.2.20 Bead counting 
A 1.7 ml tube provided with the kit was used. The tube was put in the GS Junior Bead Counter to 
estimate the number of enriched beads. The upper line of the window corresponds to 20% 
(equals 2 million beads), the lower line represents 5% (equals 500,000 beads). 
Beads were stored at +4°C until further proceeding. 
 
II.2.2.21 Deep sequencing 
The actual sequencing run was conducted following GS Junior Sequencing Method Manual 
(March 2012) [20]: 
First, kit components of the Reagents and Enzyme box were thawed: All 2.0 ml tubes were 
stored on ice to thaw. The empty container was filled with tab water. The 50 ml conical tube 
and 10-tubes Reagents-cassette were placed back in the container for thawing. Packing Beads 
and Supplement CB were kept on ice together with the 2.0 ml tubes. 
A pre-wash was conducted: Therefore all Sipper tubes in the 454 machine were replaced by 
those from the new kit. The pre-wash cassette was installed in the instrument after rinsing it 
twice with nanopure water and then filling its tubes with Pre-wash Buffer till approximately 1cm 
from the top of the tubes. The bottle of Pre-wash Buffer was placed next to an empty waste 
bottle. A used PTP device was still there in the machine. 
To the Buffer CB bottle, 6.6 ml of Supplement CB were added and contents were mixed by 
inverting the bottle 10 times. Then, 40 ml of the Buffer CB were transferred into a clean 50 ml 
conical tube and placed on ice. The Apyrase tube was spun in a centrifuge for 5 seconds at 
 
 
50 
 
10,000 rpm. 6.5 µl of Apyrase were added to the 50 ml conical tube containing CB Buffer. 
Contents were mixed by inverting the conical tube 10 times and then stored on ice. 
The bead loading gasket and cartridge seal from the PTP device tray were washed together with 
the Bead Deposition Device (BDD) in a Sparkleen solution, cleaned with a toothbrush, diligently 
rinsed with nanopure water and thoroughly dried with Kimwipes. Altogether, they were 
assembled with the PTP device. 
Four different layers were loaded onto the PTP device as follows (see table 29). Every time the 
BDD was centrifuged before loading the next layer. To keep liquid inside the BDD during 
spinning, both loading port and air vent were covered with tape. 
Bead Layer Bead Type 
Layer 1 Enzyme Beads Pre-layer 
Layer 2 DNA and Packing Beads 
Layer 3 Enzyme Beads Post-layer 
Layer 4 PPiase Beads 
         Table 29: Layers of enzymes and beads to be loaded onto the PTP device. 
Through the loading port, 350 µl of Buffer CB from the 50 ml conical tube were pipetted onto 
the PTP device. The BDD was spun for 5 minutes at 4,013 rpm. 
As 400,000 DNA beads were attempted to be sequenced because this amount of beads had 
shown to yield the best results in previous experiments, 0.32% of the 1,250,000 enriched beads 
were transferred into a new 1.7 ml tube. This was done by adjusting the volume of enriched 
beads to exactly 1 ml and then taking out 320 µl of bead suspension. Beads were then pelleted 
in a centrifuge and enough supernatant was removed to leave only 100 µl in the tube. 
Control Beads XLTF were centrifuged for 5 seconds at 10,000 rpm. After pipetting up and down 
5 times to resuspend the beads, 6 µl of them were added to the new 1.7 ml tube of enriched 
DNA beads (not more than 100 µl). 500 µl of CB Buffer from the 50 ml conical tube were added 
to the DNA Beads. The tube was vortexed and incubated for 20 minutes at room temperature 
on a lab rotator. 
Packing Beads were three times washed with 1 ml of CB buffer from the 50 ml conical tube as 
follows: CB Buffer was added, beads were centrifuged at 10,000 rpm for 5 minutes and 
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supernatant was carefully removed. After the third wash, 200 µl of CB Buffer from the 50 ml 
conical tube was added, the contents were mixed by vortexing and then stored on ice. 
1 ml of CB Buffer from the 50 ml conical tube was added to each PPiase Beads and Enzyme tube. 
Both tubes were vortexed and then put in a Magnetig Particle Collector (MPC) to pellet the 
beads. The MPC was inverted several times before letting the beads pellet completely. 
Supernatants were removed. Both bead types were washed three times with 1ml CB Buffer 
from the 50 ml conical tube, as explained before. After the third wash, 400 µl of CB Buffer from 
the 50 ml conical tube was added to the Enzyme Beads and 410 µl were added to the PPiase 
Beads. Both tubes were vortexed. Two new 1.7 ml tubes were labelled Pre-layer and Post-layer 
and prepared as follows (see table 30): 
Reagents CB Buffer (50 ml tube) Enzyme Beads Total volume 
Pre-layer 300 µl 110 µl 410 µl 
Post-layer 180 µl 230 µl 410 µl 
             Table 30: Pre-layer and Post-layer mixes. 
Both tubes were vortexed and stored on ice. 
The tube of DNA Beads was retrieved from the lab rotator and spun in a centrifuge for 10 
seconds at 10,000 rpm. Enough supernatant was removed to leave 50 µl in the tube. The 
Polymerase and Polymerase Cofactor were spun for 5 seconds at 10,000 rpm. Then, 40µl of 
Polymerase, 20 µl of Polymerase Cofactor and 65 µl of CB Buffer from the 50 ml conical tube 
were added to the DNA Beads. The mixture was vortexed and incubated on the lab rotator at 
room temperature for 10 minutes. 
Afterwards, the tube of Packing Beads was vortexed and 175 µl of them were transferred into 
the tube of DNA Beads. The DNA Beads were again incubated on the lab rotator at room 
temperature for 5 minutes. 
From the BDD device, as much supernatant as possible was carefully pipetted out through the 
port hole. After vortexing the tube of Pre-layer, 350 µl of it were promptly loaded onto the PTP 
device. The BDD was centrifuged for 5 minutes at 4,013 rpm. 
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In the meantime, 1 ml of DTT was added to the bottle of Buffer CB, after vortexing. After 
inverting the tube of Substrate TW 10 times, 44 ml of it were transferred into the bottle of 
Buffer CB. The bottle was then inverted 10 times. 
From the BDD, as much supernatant as possible was carefully pipetted out through the port 
hole. After mixing it thoroughly, 350 µl of DNA and Packing Beads suspension were loaded onto 
the PTP device. The BDD was spun again for 10 minutes at 4,013 rpm. 
In the meantime, the Pre-wash cassette and Pre-wash bottle were removed from the 454 
machine and discarded. The waste bottle was emptied and place back in the instrument. After 
changing gloves to avoid contamination, the Reagents cassette was inverted 20 times to mix. All 
caps were carefully removed, avoiding contamination from one tube to another. The Reagents 
cassette was placed in the instrument. The bottle of Buffer CB was placed next to the waste 
bottle. By clicking Proceed on the computer, the prime of the instrument was started. 
After changing gloves, as much supernatant as possible was carefully pipetted out through the 
port hole from the BDD. After vortexing, 350 µl of Post-layer were promptly loaded through the 
loading port. The BDD was spun for 10 minutes at 4,013 rpm. 
In the meantime, the used PTP device in the 454 machine was removed.  After changing the 
gloves, the surface of the cartridge was wiped with a Kimwipe and 50% ethanol. The surface of 
the PTP cartridge was cleaned with a Kimwipe and a 10% solution of Tween-20 Surfact-Amps 
Detergent Solution.  The camera was wiped with a Zeiss pre-moistened cleaning tissue.  
From the BDD, as much supernatant as possible was carefully pipetted out through the port 
hole. After vortexing, 350 µl of PPiase Beads were loaded onto the PTP device. The BDD was 
centrifuged for 5 minutes at 4,013 rpm.  
After spinning, as much supernatant as possible was carefully pipetted out through the port 
hole from the BDD. The PTP device was removed from the BDD and inserted onto the cartridge 
seal in the 454 instrument. The back of the PTP device was cleaned with a Kimwipe, the camera 
door was closed and the sequencing run was started. 
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II.2.2.22 Analysis 
Data from the sequencing run was analyzed with the help of GS Junior 454 Sequencing System 
Software Manual, v 2.5p1 (August 2010) [21]. As reference sequence, against which the 
sequencing reads are aligned and compared so variations can be detected, served a HCV 1b NS3 
sequence. Multiplex Identifiers (MIDs) helped identifying the single amplicons. 
 
 
II.2.3 Plasma Samples Experiment 
II.2.3.1 Primer generating / Fusion primer design 
Amplicon Primers were designed with the help of IDT-Integrated DNA Technologies, using a HCV 
1a, 1b, 1c consensus sequence as reference sequence. According to 454 Sequencing System 
Guidelines for Amplicon Experimental Design (July 2011), deep sequencing requires amplicons 
between 200 and 600 bp in length, including adapter sequences [22]. The selected amplicons 
for this project are located in NS2/NS3p (NS3p Amp9) and in NS5b. The first one starts in NS2 at 
position 554 and covers the first part of NS3p until position 329. It is 427 bp long (including 
primers). 
Deep sequencing primers contain a certain adapter sequence, key (TCAG) and Multiplex 
Identifier sequence (MID) which are important for binding to capture beads during emPCR and 
sequencing primers as well as identification of the amplicon during analysis.  
The amplicon in NS5b contains 434 bp (including primers). It starts at position 661 of NS5b and 
ends at position 1094. 
 
II.2.3.2 Primer optimization (primer tests) NS3p Amp9, NS5b C316 
Primers generating amplicons for deep sequencing have to be very exact, leaving no short 
secondary products (as described in section II.2.2.9) 
 
 
54 
 
With a standard polymerase chain reaction, the primer pairs NS3p Amp9 MID1 fw, rev and NS5b 
C316 MID1 fw, rev were tested (see tables 31–40). Products were run on a 1.5% agarose 
electrophoresis gel to look for secondary bands showing short products (as described in section 
II.2.2.12). Temperature and concentration showing the best conditions (clear band, no 
secondary faint bands) were used for further experiments. 
The fw primer of NS3p Amp9 is located in NS2. Therefore the primer pair was tested on a 
1a.US.77.H77 plasmid, which covers both NS2 and NS3. A concentration gradient for NS5b fw 
and rev was tested on a HCV 1b 5.1 Replicon plasmid.  For the temperature gradient, both the 
HCV 1b 5.1 Replicon plasmid and a 1a.US.77.H77 plasmid were used. The concentration 
gradient was created as explained in section II.2.2.9. Phusion Buffer and DNA Polymerase were 
used. 
Volume (µl) Reagent Concentration 
16.8 ddH2O   
5 Buffer   
0.5 dNTP Mix 10 mM 
0.625 Primer Forward 10 µM   NS3p Amp9 MID1 
0.625 Primer Reverse 10 µM   NS3p Amp9 MID1 
1 pH77/deltaE1-p7 5 ng/µl 
0.5 DNA Polymerase (phusion) 2 units/µl 
total: 25 
 Table 31: Master Mix primer test NS3p Amp9 MID1 temperature gradient. 
PCR Program Temperature Time   
Step 1 Initial Denaturation 98°C 30 sec 
30 cycles 
Step 2 Denaturation 98°C 10 sec 
Step 3 Annealing 
52.5°C 
30 sec 
56.5°C 
61.8°C 
64.5°C 
69.1°C 
Step 4 Extension 72°C 15 sec 
Step 5 Extension 72°C 7 min 
Step 6 Hold 4°C 
    Table 32: PCR program primer test NS3p Amp9 MID1 temperature gradient. 
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Volume (µl) Reagent Concentration 
13 ddH2O   
5 Buffer   
0.5 dNTP Mix 10 mM 
2.5 Primer Forward 10 µM   NS3p Amp9 MID1 
2.5 Primer Reverse 10 µM   NS3p Amp9 MID1 
1 pH77/deltaE1-p7 5 ng/µl 
0.5 DNA Polymerase (phusion) 2 units/µl 
total: 25 
 Table 33: Master Mix primer test NS3p Amp9 MID1 concentration gradient. 
 
PCR Program Temperature Time   
Step 1 Initial Denaturation 98°C 30 sec 
30 cycles Step 2 Denaturation 98°C 10 sec Step 3 Annealing 56.5°C 30 sec 
Step 4 Extension 72°C 15 sec 
Step 5 Extension 72°C 7 min 
Step 6 Hold 4°C 
    Table 34: PCR program primer test NS3p Amp9 MID1 concentration gradient. 
 
Volume (µl) Reagent Concentration 
13.7 ddH2O   
5 Buffer   
0.5 dNTP Mix 10 mM 
2.5 Primer Forward 10 µM   NS5b C316 MID1 
2.5 Primer Reverse 10 µM   NS5b C316 MID1 
0.29 5.1 Replicon plasmid 17.3 ng/µl 
0.5 DNA Polymerase (phusion) 2 units/µl 
total: 25 
 Table 35: Master Mix primer test NS5b C316 MID1 temperature gradient with 5.1 replicon plasmid. 
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PCR Program Temperature Time   
Step 1 Initial Denaturation 98°C 30 sec 
30 cycles 
Step 2 Denaturation 98°C 10 sec 
Step 3 Annealing 
51.0°C 
30 sec 
52.5°C 
56.5°C 
61.8°C 
64.5°C 
Step 4 Extension 72°C 15 sec 
Step 5 Extension 72°C 7 min 
Step 6 Hold 4°C 
    Table 36: PCR program primer test NS5b C316 MID1 temperature gradient with 5.1 replicon plasmid. 
 
Volume (µl) Reagent Concentration 
13.7 ddH2O   
5 Buffer   
0.5 dNTP Mix 10 mM 
2.5 Primer Forward 10 µM   NS5b C316 MID1 
2.5 Primer Reverse 10 µM   NS5b C316 MID1 
1 pH77/deltaE1-p7 5 ng/µl 
0.5 DNA Polymerase (phusion) 2 units/µl 
total: 25 
  Table 37: Master Mix primer test NS5b C316 temperature gradient with pH77/deltaE1-p7. 
 
PCR Program Temperature Time   
Step 1 Initial Denaturation 98°C 30 sec 
30 cycles 
Step 2 Denaturation 98°C 10 sec 
Step 3 Annealing 
51.0°C 
30 sec 
52.5°C 
56.5°C 
61.8°C 
64.5°C 
Step 4 Extension 72°C 15 sec 
Step 5 Extension 72°C 7 min 
Step 6 Hold 4°C 
     Table 38: PCR program primer test NS5b C316 temperature gradient with pH77/deltaE1-p. 
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Volume (µl) Reagent Concentration 
13.7 ddH2O   
5 Buffer   
0.5 dNTP Mix 10 mM 
2.5 Primer Forward 10 µM   NS5b C316 MID1 
2.5 Primer Reverse 10 µM   NS5b C316 MID1 
0.29 5.1 Replicon plasmid 17.3 ng/µl 
0.5 DNA Polymerase (phusion) 2 units/µl 
total: 25 
  Table 39: Master Mix primer test NS5b C316 MID1 concentration gradient with 5.1 replicon plasmid. 
 
PCR Program Temperature Time   
Step 1 Initial Denaturation 98°C 30 sec 
30 cycles Step 2 Denaturation 98°C 10 sec Step 3 Annealing 56.5°C 30 sec 
Step 4 Extension 72°C 15 sec 
Step 5 Extension 72°C 7 min 
Step 6 Hold 4°C 
     Table 40: PCR program primer test NS5b C316 MID1 concentration gradient with 5.1 replicon plasmid. 
 
II.2.3.3 RNA extraction 
RNA was extracted from the 28 plasma samples on 2 different days (first 8 samples on July 30th, 
then 20 more samples on August 6th 2014), following instructions of Qiagen RNeasy Mini Kit 
(June 2012) [17]. In order not to contaminate the samples with DNA from plasmids and to get 
some safety instructions on how to handle infectious blood plasma, the extraction was 
conducted at the Lady Davis Institute (LDI) Montreal. Plasma and extracted RNA where shipped 
on dry ice. From the 28 samples, 16 were used for deep sequencing in the end.  
At the first RNA extraction, RNA was eluted in 60 µL of Buffer AVE, as recommended in the 
Qiamp Viral RNA Mini Handbook (June 2012) [23]. The second time, to increase the final 
concentration, RNA was eluted in only 30 µL.  
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As a negative control, RNase-free water instead of plasma was added to one reaction per RNA 
extraction. 
 
II.2.3.4 Reverse transcription 
The negative controls from the RNA extractions were further used to the reverse transcription. 
As positive control served RNA WT NS3 in pET 21b and 1a.US.77.H77 
For targets bigger than 2kb, Agilent AccuScript High Fidelity 1st Strand cDNA Synthesis Kit 
Instruction Manual recommends an input of 200-5000ng of RNA to the reaction [24]. Up to 11 µl 
of RNA can be added. As the main part of eluted RNA from the RNA extraction is carrier RNA, to 
simplify calculations only carrier RNA was taken into calculating the quantity of RNA added to 
the reaction. 
5600ng of carrier RNA in 60 µL of Buffer AVE equals 93.3 ng/µL. When multiplied by 11, because 
up to 11 µl of RNA can be added, this equals 1026.3 ng, which is within the recommended 
quantity for a target bigger than 2 kb. 
5600 ng/30 µL = 186.7 ng/µL. When multiplied by 11 this equals 2057 ng. 
For all reverse transcriptions, the maximum volume (=11 µl) was added.  
The reverse transcription was conducted following this protocol (tables 41, 42, 43): 
Volume (µl) Reagent Concentration 
0 ddH2O   
2 AccuScript RT Buffer   
1 Random Primer   
2 dNTP 10mM 
11 RNA 
  
  
  
total: 16.5 
  Table 41: Master Mix Reverse transcription Plasma Samples Experiment. 
 
 
59 
 
The mix was incubated at 65°C for 5 minutes, then briefly cooled at room temperature for 5 
minutes. The following components were added: 
Volume (µL) Reagents Concentration 
2 DTT 100 mM 
1 Accuscript RT 40 U/µl 
0.5 Rnase Inhibitor   
       Table 42: Master Mix 2 Reverse transcription Plasma Samples Experiment. 
 The following program was run: 
  Temperature Time 
Preheat 25°C 10 min 
  42°C 60 min 
  70°C 10 min 
Hold 4°C   
       Table 43: Reverse transcription program Plasma Samples Experiment. 
cDNA was stored at -20°C until further proceeding. 
 
II.2.3.5 qPCR 
19 extracted cDNA samples as well as two WT controls (one from a 1a.US.77.H77 plasmid and 
one from RNA) were compared to 14 standards and one blank, containing RNase-free water. 
The 14 standards are dilutions from a HCV 1b plasmid.  
Real Time PCR was conducted following this protocol (see tables 44 and 45): 
Reagents 
Volume 
(µl) 
Green-2-go Mastermix 10 
Forward Primer 10uM 1 
Reverse Primer 10 uM 1 
PCR Water 7 
Template 1 
  Table 44 qPCR Mastermix. 
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qPCR Program 
        
  
Temperature 
(ºC) Time   
Hold 95 10 minutes   
Place 
# Description Conc. unit 
Cycling 95 30 seconds   1 
Standard                            
HCV1b Neo WT 
1.5625 ng/µl 
  59 60 seconds   2 0.78125 ng/µl 
  72 90 seconds   3 0.390625 ng/µl 
Melt 72 - 95       4 0.195313 ng/µl 
Rising 1 degree each step   5 0.097656 ng/µl 
45 second wait after 1st step   6 0.048828 ng/µl 
Then 5 second wait after each step afterwards   7 0.024414 ng/µl 
8 0.012207 ng/µl 
9 0.006104 ng/µl 
10 0.003052 ng/µl 
11 0.001526 ng/µl 
12 0.000763 ng/µl 
 
 
13 0.000381 ng/µl 
14 0.000191 ng/µl 
15 Blank 
    
16 A12-02 
    
17 A24-10 
    
18 A42-10 
    
19 A57-10 
    
20 A61-11 
    
21 A85-03 
    
22 A93-03     
23 A94-01     
24 B05-08     
25 B49-03     
26 B51-01     
27 B84-01     
28 C01-15     
29 A76-05     
30 B33-05     
31 B35-04     
32 B37-03     
33 B57-01     
34 C06-01     
35 WT control from plasmid     
36 WT control from RNA     
Table 45: qPCR protocol Plasma Samples Experiment. 
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II.2.3.6 Amplicon PCR 
Following the protocols as shown in tables 50, 51, 52 and 53, four different PCRs were 
conducted in order to get enough samples working for deep sequencing. For some, 
amplification was not or not sufficiently possible, due to either damage at shipping or a failure 
of the reverse transcription or amplicon PCR.  The negative control used for the RNA extraction 
was included in the reactions (-Ve), as well as several other negative controls, containing RNase-
free water instead of a sample (-Ve (H2O)). 
Despite the fact that the NS3p fw primer is located in NS2-region, a NS3-NS5b replicon plasmid 
was used as a positive control for the first two reactions, showing obviously no band on the gel. 
For the third reaction a standard material (strain 1a.US.77.H77) was used, giving a strong band. 
The fourth reaction was for NS5b samples and therefore HCV 1b 5.1 Replicon plasmid served as 
positive control. Phusion Buffer and DNA Polymerase were used. 
Primers NS3p Amp9 MIDx fw and rev were used for the first 3 reactions, NS5b MIDx fw and rev 
for the last PCR. Samples and MIDs were assembled as follows (see tables 46, 47, 48, 49): 
cDNA MID  cDNA MID 
A12-02 MID 2  B05-08 MID 2 
A24-10 MID 3  B51-01 MID 3 
A42-10 MID 4  B49-03 MID 4 
A57-10 MID 5  B57-01 MID 5 
A61-11 MID 6  A76-05 MID 6 
A85-03 MID 7  B33-05 MID 7 
A93-03 MID 8  B35-04 MID 8 
A94-01 MID 9  B37-03 MID 9 
WT control   MID 10  WT control   MID 10 
-Ve MID 2  -Ve MID 2 
-Ve (H2O) MID 3  -Ve (H2O) MID 3 
-Ve (H2O) MID 4  -Ve (H2O) MID 5 
-Ve (H2O) MID 5  -Ve (H2O) MID 7 
       
 
 
 
Table 46: Assignment of MIDs to plasma samples first 
amplicon PCR. 
Table 47: Assignment of MIDs to plasma samples second 
amplicon PCR. 
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cDNA MID  cDNA MID 
C01-15 MID 6  A76-05 MID 6 
B84-01 MID 7  B33-05 MID 7 
WT control  MID 10  B35-04 MID 8 
-Ve (H2O) MID 6  B37-03 MID 9 
   B57-01 MID 5 
   C06-01 MID 4 
   A24-10 MID 4 
   A42-10 MID 3 
   A57-10 MID 2 
   A85-03 MID 7 
   A93-03 MID 6 
   WT control   MID 10 
   -Ve MID 9 
   -Ve (H2O) MID 8 
   -Ve (H2O) MID 7 
   -Ve (H2O) MID 6 
 
 
Volume (µl) Reagent Concentration 
14.5 ddH2O   
5 Buffer   
0.5 dNTP Mix 10 mM 
1.25 Primer Forward 10 µM   NS3p Amp9 MIDx 
1.25 Primer Reverse 10 µM   NS3p Amp9 MIDx 
2 cDNA from plasma   
0.5 DNA Polymerase (phusion) 2 units/µl 
total: 25 
Table 50: Master Mix plasma samples from first and second RNA extraction using NS3p Amp9. 
 
PCR Program Temperature Time   
Step 1 Initial Denaturation 98°C 30 sec 
30 cycles Step 2 Denaturation 98°C 10 sec Step 3 Annealing 56.5°C 30 sec 
Step 4 Extension 72°C 15 sec 
Step 5 Extension 72°C 7 min 
Step 6 Hold 4°C 
     Table 51: PCR program plasma samples from first and second RNA extraction using NS3p Amp9. 
 
Table 48: Assignment of MIDs to plasma samples 
third amplicon PCR. 
Table 49: Assignment of MIDs to plasma samples fourth 
amplicon PCR. 
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Volume (µl) Reagent Concentration 
14.5 ddH2O   
5 Buffer   
0.5 dNTP Mix 10 mM 
1.25 Primer Forward 10 µM   NS5b C316 MIDx 
1.25 Primer Reverse 10 µM   NS5b C316 MIDx 
2 cDNA from plasma   
0.5 DNA Polymerase (phusion) 2 units/µl 
total: 25 
Table 52: Master Mix plasma samples from first and second RNA extraction NS5b. 
 
PCR Program Temperature Time   
Step 1 Initial Denaturation 98°C 30 sec 
30 cycles Step 2 Denaturation 98°C 10 sec Step 3 Annealing 54.2°C 30 sec 
Step 4 Extension 72°C 15 sec 
Step 5 Extension 72°C 7 min 
Step 6 Hold 4°C 
     Table 53: PCR program plasma samples from first and second RNA extraction NS5b. 
 
 
II.2.3.7 Library purification 
Library purification was conducted according to the GS Junior Library Preparation Method 
Manual (March 2012) [18] as described for the Mutant Mix Experiment (section II.2.2.13). 
 
II.2.3.8 Library Quality Control PCR (QCPCR) 
Library Quality Control PCR was conducted according to the GS Junior Library Preparation 
Method Manual (March 2012) [18] as described for the Mutant Mix Experiment (section 
II.2.2.14). 
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II.2.3.9 Bioanalyzer 
Purified samples and amplicons were sent to another lab to be run on Agilent 2100 Bioanalyzer 
system as described for the Mutant Mix Experiment (section II.2.2.15). 
 
II.2.3.10 PicoGreen Quantification (Library Quantitation) 
PicoGreen Quantification was conducted according to the GS Junior Library Preparation Method 
Manual (March 2012) [18] as described for the Mutant Mix Experiment (section II.2.2.16). 
For NS5b the concentration of the WT control was higher than the highest standard curve value. 
Therefore this sample was diluted 1/2 and re-measured immediately. For the calculation, the 
dilution factor 2 was taken into account. 
 
II.2.3.11 Amplicon dilution and pooling 
Amplicon dilution and pooling was conducted according to the GS Junior Library Preparation 
Method Manual (March 2012) [18] as described for the Mutant Mix Experiment (section 
II.2.2.17). 
All three amplicon libraries were pooled and the mix was brought to a final concentration of 
2x105 molecules/µl. 
 
II.2.3.12 emPCR 
The emPCR was conducted according to the GS Junior emPCR Amplification Method Manual Lib-
A (May 2010) [19] as described for the Mutant Mix Experiment (section II.2.2.18). 
Previous experiments had shown that the enrichment can be too high when using the 2 
molecules per µl recommended by the manual. That is why for the samples from the first RNA 
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extraction, the desired number of molecules per bead was 1. Therefore 25 µl of the samples 
pool were used. 
As the enrichment from the emPCR of the samples from the first RNA extraction was 5% and 
therefore at the lower end of the window, the attempted number of molecules per bead for 
samples from the second RNA extraction was 1.2, and 30 µl of the pooled samples were used. 
For NS5b, 1.1 molecules per bead were desired and therefore 27.5 µl of the pool were used. 
 
II.2.3.13 Bead recovery and enrichment 
Bead recovery and enrichment were conducted according to the GS Junior emPCR Amplification 
Method Manual Lib-A (May 2010) [19] as described for the Mutant Mix Experiment (section 
II.2.2.19). 
 
II.2.3.14 Bead counting 
Beads were counted according to the GS Junior emPCR Amplification Method Manual Lib-A 
(May 2010) [19] as described for the Mutant Mix Experiment (section II.2.2.20).  
 
II.2.3.15 Deep sequencing 
Deep sequencing was conducted according to the GS Junior Sequencing Method Manual (March 
2012) [20] as described for the Mutant Mix Experiment (section II.2.2.21). 
As described in section II.2.2.21, for all three deep sequencing runs, a little less than the 
recommended amount of enriched beads was loaded onto the PTP. 
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II.2.3.16 Analysis 
Data from the sequencing run was analyzed with the help of GS Junior 454 Sequencing System 
Software Manual, v 2.5p1 (August 2010) [21], as explained in section II.2.2.22. For both NS5b 
and the protease region a 1a.US.77.H77 plasmid was used as a reference sequence.  
Multiplex Identifiers (MIDs) helped identifying the single amplicons. 
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III Results 
III.1 Mutant Mix Experiment 
III.1.1 Primer optimization (primer tests) NS3p Amp7  
The first gel picture (figure 4) shows the concentration gradient for the primer pair NS3p Amp7 
MID1 forward and reverse. The amplicon created with the help of those primers (NS3p Amp7) 
contains all three mutants of the first experiment: S122R, R155K and D168V. As explained in 
chapter II.2.2.9, an HCV 1b 5.1 Replicon plasmid served as template. Due to the fact that a 
higher annealing temperature is associated with a higher specificity of the primers —a low 
annealing temperature promotes false binding sites— the concentration gradient was 
conducted using a high annealing temperature (64.5°C). Subsequently, in a second run, different 
temperatures were tested to find the best working annealing temperature, as shown in the 
second gel picture (figure 5). In further experiments, 0.25 µM were used as final concentration 
of the primers in the reaction mix while 52.5°C were used as annealing temperature. 
                   
 
 
Figure 4: Primer test NS3p Amp7 MID1 
concentration gradient with six different 
concentrations from 1 µM to 0.03125 µM. 
Figure 5: Primer test NS3p Amp7 MID1 temperature 
gradient using seven different annealing temperatures 
from 51.0°C to 64.5°C at a concentration of 0.25 µM. 
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III.1.2 qPCR 
A Real Time quantitative PCR (qPCR) was conducted to quantify the six products of the reverse 
transcription. Those measurements were compared to 14 reference measurements with known 
concentrations. Results are shown in table 54. Standard number 14 was left out of the analysis 
because its tube opened during the reaction. Although the measured concentrations of the six 
cDNA samples do not decouple each time going from the lowest to the highest concentration, 
one might conclude that the measured amount of cDNA multiplies in each process. However, 
the concentrations of the cDNA samples now do not resemble exactly the original 
concentrations at RNA level, which can mean that the reverse transcription had worked better 
on some of the samples than others. But it is certainly enough to conclude that the reverse 
transcription had worked for at least five of the six samples. As for the sample with originally 
the lowest concentration (50 fg/µl), the reverse transcription might not have worked properly 
which is why it then does not show on the gel from the amplicon PCR in chapter III.1.3. 
 
Place # description measured conc. unit 
15 Blank 0.000063 ng/µl 
16 Mutant Mix 5 ng/µl cDNA 0.421567 ng/µl 
17 Mutant Mix 0.5 ng/µl cDNA 0.050026 ng/µl 
18 Mutant Mix 50 pg/µl cDNA 0.012178 ng/µl 
19 Mutant Mix 5 pg/µl cDNA 0.002353 ng/µl 
20 Mutant Mix 0.5 pg/µl cDNA 0.000462 ng/µl 
21 Mutant Mix 50 fg/µl cDNA 0.000111 ng/µl 
22 pET in 21b WT control 2.6821 ng/µl 
Table 54: qPCR results without standards Mutant Mix Experiment. 
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Figure 6 shows the standard curve of the reaction. The Ct value (Cycle Threshold) of each 
sample and standard except standard 14 is shown against their concentrations. R is 0.96172, 
indicating an acceptable alignment of the data points and therefore reliable results of the qPCR. 
The efficiency is 0.65, indicating that the reaction itself did not run ideally. This observation is in 
accordance to the fact that the graphs in figure 7 sometimes do not reach a plateau. 
 
 
 
Figure 6: qPCR standard curve Mutant Mix Experiment showing the Ct value of each standard 
(blue) and sample (red) against their concentrations. 
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Figure 7 shows the intensity of a fluorescence signal as an indicator for amplification of all 
standards and samples (except standard number 14) during 40 cycles.  The WT control gives the 
strongest signal, even stronger than the highest standard. The baseline for all curves is flat and 
their linear phases are long. However some samples do not reach a plateau due to the fact that 
their initial concentration was low, i.e. more cycles would have been necessary to get the 
samples to reach a steady state. The samples rise in order from highest to lowest concentration. 
As mentioned before, these results indicate that the reverse transcription had worked which 
allowed a continuation of further experiments.  
 
Figure 7: qPCR Mutant Mix Experiment showing amplification of the WT control, six samples and 14 standards during 40 
cycles.  
 
 
 
 
III.1.3 Amplicon PCR 
An amplicon PCR was conducted on the six rever
original concentrations of 5 ng
primer pair NS3p Amp7 MIDx forward and reverse. The plasmid WT NS3 in pET 21b served as 
positive control. The samples
the bands decreases from 5 ng
This was already suggested by 
dilution was therefore not used for further experiments
as expected (see figure 8). 
 
 
 
Figure 8: Amplicon PCR Mutant Mix Experiment showing 
six samples of  double stranded DNA at original 
concentrations ranging from 5 ng/µl to 50 fg/µl on the 
agaro
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se transcription products
/µl, 0.5 ng/µl, 50 pg/µl, 5 pg/µl, 0.5 pg/µl 
 show clear, single bands on the agarose gel
/µl to 0.5 pg/µl, with no visible band left of the 50
the low concentration of this sample after the qPCR. The 50fg/µl 
. Positive and negative controls are both 
 
se gel. 
 
 “Mutant Mix” at 
and 50 fg/µl using the 
. The perceptibility of 
 fg/µl dilution. 
 
 
III.1.4 Quality Control PCR (QCPCR)
After Library Purification as described in chapter II.2.2.13, a Quality Control PCR was conducted 
on the five remaining samples
ng/µl, 50 pg/µl, 5 pg/µl, and 0.5
clear bands. The negative control show
provided by GS Junior.  
 
 
 
III.1.5 Bioanalyzer 
In order to look for smaller by
sequencing, QCPCR products as well as the purified amplicons were sent to another lab to be 
run on the Agilent 2100 Bioanalyzer system. 
sequenced in pairs, for efficiency reasons. One good
The two peaks which are labelled in green 
Figure 9: QCPCR Mutant Mix Experiment with five 
samples as well as the positive control showing 
distinct, strong bands on the gel.
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 from the amplicon PCR at original concentrations of
 pg/µl. All of them, as well as the WT control 
s no band (see figure 9). Primers for the reaction were 
 
-products of the reactions which can later interfere with deep 
The QCPCR samples were pooled together and 
 Bioanalyzer result is shown
and purple represent the ladder
 
 
 5 ng/µl, 0.5 
show strong single, 
 in figure 10. 
. One single, distinct 
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peak in the middle between 80 and 85 bp shows the sample. There are no additional smaller 
peaks and the baseline is flat, without any undefined extra peaks.  
 
    
 
 
In comparison, the scan of the bioanalyzer at this time with the most additional peaks is shown 
in figure 11. Because it is mainly the short fragments which can interfere with deep sequencing, 
even the extra peaks in this picture at 92 – 95.64 seconds were not deemed important as they 
are larger than the sample and also are in their intensity about 0.04% of the amount of the 
sample. Peak heights are related to quantity. The lower the peak, the less DNA is present. The 
Mutant Mix 50 pg/µl 
Figure 10: Bioanalyzer result 50 pg/µl Mutant Mix Experiment showing a fluorescent signal 
representing the quantity of DNA in a reaction between 40 to 120 seconds as well as two ladders at 
43.00 and 113.00 seconds. 
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single peaks at 79.12 and 83.83 seconds are that close to the sample, that they represent most 
likely denaturated DNA belonging to the sample, and not contamination.  
For the remaining electropherograms, see the appendix. 
 
 
Figure 11: Bioanalyzer result 0.5 pg/µl Mutant Mix Experiment with several small additional peaks. 
 
Mutant Mix 0.5 pg/µl 
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III.1.6 PicoGreen Quantification (Library Quantitation) 
The library was quantified using PicoGreen Quantification. All values of the samples fall within 
the range of the standards. The R value is higher than 0.98, as recommended in GS Junior 
Library Preparation Method Manual (March 2012) [18], suggesting that the results of the 
quantification are reliable. As expected, the WT control shows the highest concentration while 
the amount of library DNA of the samples decreases from the originally 5 ng/µl sample to the 
0.5 pg/µl sample (see figure 12). 
 
Figure 12: PicoGreen results from Mutant Mix Experiment showing the amount of DNA in the five samples plus the wild type 
control. 
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III.1.7 Enrichment 
The enriched capture beads were counted using GS Junior Bead Counter. White enriched beads 
show exactly in the middle between upper (20%) and lower (5%) line of the window, resulting in 
an enrichment of 12.5% (see figure 13). Loading to little DNA onto the plate for the deep 
sequencing run results in good quality but low data output, while too much amount of DNA 
leads to poor image resolution and problems with the analysis. Also, experience from previous 
experiments had shown that an amount of approximately 400,000 beads for the deep 
sequencing run leads to satisfying results. That is why 0.32% of those enriched beads were used 
for the run. 
 
 
 
 
III.1.8 Numbers from the run 
There are some criteria to determine whether a deep sequencing run was successful. For 
instance, GS Junior recommends the ratio of Passed Filter Wells / Key Pass Wells to be higher 
than 25–50% and Key Pass Wells / Total Raw Wells to be higher than 90%. In this case, Raw 
Wells means the number of all detected signals on the plate during the run, while Key Pass 
Wells equals all the Raw Wells starting with a valid key sequence. Passed Filter Wells are the 
Figure 13: Enrichment Mutant Mix Experiment showing white capture beads filling out 
exactly the lower half of the window, resulting in an enrichment of about 12.5% or 
1,250,000 beads.  
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total of reads which pass all of the program’s filters. In this experiment, Passed Filter Wells/ Key 
Pass Wells was 0.55 or 55% while Key Pass Wells / Total Raw Wells was 0.97 or 97%, and 
therefore within the recommended range by GS Junior Data Analysis Terminology and 
Benchmarks [25] (see table 55). 
 
TCAG (Library) Region Total 
Raw Wells 187,291 187,291 
Key Pass Wells 180,795 180,795 
Passed Filter Wells 99,807 99,807 
Total bases 39,030,823 39,030,823 
Average Read Length 391,06 391,06 
Length Std Deviation 30,09  
Longest Read Length 720 720 
Shortest Read Length 40 40 
Median Read Length 393.0 393.0 
Modal Read Length 393.0 393.0 
   Table 55: Numbers from the deep sequencing run of the Mutant Mix Experiment. 
 
 
III.1.9 Deep sequencing results 
Deep sequencing results from the region of interest are shown in table 56. Variants 
corresponding to the codon changes for S122R, D168V and R155K are highlighted. As the 
mutant codon R155K differs in two bases from its wild-type (positions 463 and 464), both 
variants were combined by the software and the common percentage was defined. 
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Table 56: Deep sequencing results, original percentages and codon changes Mutant Mix Experiment. 
 
In order to be able to compare the deep sequencing results back to the original percentages, 
the error for each result was calculated (see table 57). Numbers from the WT differ the least 
from their originals. But even for sample with the lowest concentration, the results are valid. 
In % 
Error = ((measured value - original value)/original value) *100% 
5 ng/µl 0.5 ng/µl 50 pg/µl 5 pg/µl 0.5 pg/µl 
WT 4.52 4.26 3.6 1.86 -1.98 
S122R -29.25 -23.67 -21.83 -11.08 13.17 
R155K -18.89 -30.74 -19.63 -11.85 0 
D168V 3.33 16.67 -6.67 13.33 23.33 
Table 57: Error calculation for deep sequencing results Mutant Mix Experiment. 
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III.2 Plasma Samples Experiment 
III.2.1 Primer optimization (primer tests) NS3p Amp9, NS5b C316 
The primer pairs NS3p Amp9 MID1 forward and reverse and NS5b C316 MID1 forward and 
reverse were tested in order to find the best concentrations and annealing temperatures. 
Because the forward primer of the amplicon NS3p Amp9 is located in the NS2 region, as 
explained in chapter II.2.3.2 the primer pair was tested on a 1a.US.77.H77 plasmid covering 
both NS2 and NS3.  
As for NS3p Amp9, first a temperature gradient was conducted using five different annealing 
temperatures (see figure 14). Because a high primer concentration is associated with the 
building of primer-dimers and other short by-products, a comparatively low primer 
concentration of 0.25 µM was used for the temperature test. Then the primer pair was tested at 
six different concentrations (1, 0.5, 0.25, 0.125, 0.06, 0.03 µM) at an annealing temperature of 
56.5°C (see figure 15). This temperature was also used as annealing temperature for the 
amplicon PCR, while 0.5 µM were further used as final primer concentration in the reaction mix.  
  
 
 
Figure 14: Primer test NS3p Amp9 MID1 temperature 
gradient using five different annealing temperatures at a 
primer concentration of 0.25 µM. 
Figure 15: Primer test NS3p Amp9 MID1 concentration gradient 
with six different concentrations from 1 to 0.03 µM. 
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The primer pair NS5b C316 forward and reverse was tested on both a HCV 1b 5.1 Replicon 
plasmid and a 1a.US.77.H77 plasmid for the temperature gradient, whereas for the 
concentration gradient only the HCV 1b 5.1 Replicon plasmid was used (see figures 16 and 17). 
The temperature gradient was conducted at a primer concentration of 1 µM. Previous 
temperature gradients at a primer concentration of 0.5 µM had not worked, showing no bands 
on the gel for any of the different annealing temperatures, which is why the PCR was repeated 
at a higher primer concentration and with two different plasmids. As the concentration gradient 
shows, the primer pair should actually work at a lower concentration as well. Why the 
temperature gradient hadn’t worked previously could not be determined. 
For the primer pair NS5b C316 fw and rev, 54.2°C, which is the program’s next temperature step 
between the two best working temperatures 52.5°C and 56.5°C was further used as annealing 
temperature. As final primer concentration in the reaction mix 0.5 µM was used. 
 
  
 
 
 
 
 
Figure 16: Primer test NS5b C316 temperature gradient using five 
different annealing temperatures at a primer concentration of 1 
µM on two different plasmids. 
Figure 17: Primer test NS5b C316 concentration 
gradient using the 5.1 Replicon plasmid as template 
with six different concentrations at an annealing 
temperature of 56.5°C. 
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III.2.2 qPCR 
As described in chapter II.2.3.5, a Real Time quantitative PCR (qPCR) was conducted to quantify 
the 19 products of the reverse transcription in comparison with 14 standards with known 
concentrations. Results are shown in table 58, along with the blank and two wild-type controls. 
 
Place # description measured conc. unit 
15 Blank 0.0000381 ng/µl 
16 A12-02 0.0001747 ng/µl 
17 A24-10 0.0003161 ng/µl 
18 A42-10 0.0001978 ng/µl 
19 A57-10 0.0002128 ng/µl 
20 A61-11 0.0006115 ng/µl 
21 A85-03 0.0005432 ng/µl 
22 A93-03 0.0003022 ng/µl 
23 A94-01 0.0012086 ng/µl 
24 B05-08 0.0001502 ng/µl 
25 B49-03 0.0005899 ng/µl 
26 B51-01 0.0003343 ng/µl 
27 B84-01 0.0002768 ng/µl 
28 C01-15 0.0038123 ng/µl 
29 A76-05 0.0035481 ng/µl 
30 B33-05 0.0003057 ng/µl 
31 B35-04 0.0007062 ng/µl 
32 B37-03 0.0004122 ng/µl 
33 B57-01 0.0003937 ng/µl 
34 C06-01 0.0002227 ng/µl 
35 WT control from plasmid 3.2789139 ng/µl 
36 WT control from RNA 0.0109424 ng/µl 
           Table 58: qPCR results without standards Plasma Samples Experiment. 
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Figure 18 shows the standard curve of the reaction. As explained in chapter III.1.2, the Ct value 
(Cycle Threshold) of each sample and standard is shown against their concentrations. R is 
0.96441, indicating a good alignment of the data points and therefore reliable results of the 
qPCR. The efficiency is 0.44, indicating that the reaction itself did not run ideally.  
 
 
 
 
Figure 19 shows the intensity of fluorescence of all standards and samples during 40 cycles.  The 
WT control from plasmid gives the strongest signal, even stronger than the highest standard. 
The baseline for all curves is flat, linear phases are long, but some samples do not reach a 
plateau, indicating that their concentration was low at the start of the reaction.  But since they 
all enter the linear phase and differ clearly from the blank, the reverse transcription must have 
worked sufficiently, so they were all used for the following experiments.  
Figure 18: qPCR standard curve Plasma Samples Experiment showing the Ct value of each 
standard (blue) and sample (red) against their concentrations. 
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III.2.3 Amplicon PCR 
The following gel pictures (figures 20–23) show the results of four different polymerase chain 
reactions. As some samples show no or only faint bands on the gels (A12-02, A61-11, B33-05), 
amplification of them was unfortunately not successful. This could be either due to damage at 
shipping and storing or a failure of the reverse transcription or amplicon PCR. The sample B33-
05 was immediately left out, samples A12-02 and A61-11 were purified, but then left out and 
not used for the actual deep sequencing run, because the quality control PCR was not 
successful. In figures 20 and 21, the positive controls are not visible, due to the fact that a NS3 
plasmid had been used even though the forward primer is located in the NS2 region. Positive 
controls serve to show that the mix and amplification conditions were correct. As most of the 
samples were successfully amplified, the reaction conditions and the mix had obviously worked. 
Figure 19: qPCR Plasma Samples Experiment showing amplification of two WT controls, all samples and 
14 standards during 40 cycles. 
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So the experiment was accepted without repetition. The positive controls in figures 22 and 23 
however show strong bands. More importantly, the negative controls in all four PCR gels are as 
expected. 
For the three deep sequencing runs, from genotype 1a samples A24-10, A42-10, A57-10, A85-
03, A93-03, A94-01, B05-08, B49-03, B51-01, B84-01, C01-15, and from the genotype 1b A76-05, 
B35-04, B37-03, B57-01 and C06-01 were used. 
 
           Figure 20: Amplicon PCR plasma samples from 1st RNA extraction, NS3. 
 
       
   Figure 21: Amplicon PCR plasma samples from 2nd RNA extraction, NS3. 
 
Figure 22: Amplicon PCR plasma 
samples 2nd RNA extraction, NS3 only 
2 samples. 
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   Figure 23: Amplicon PCR plasma samples NS5b. 
 
 
III.2.4 Library quality control PCR (QCPCR) 
In all the gels (figures 24, 25), the positive control is positive, negative controls are negative. 
Samples show single, clear bands and no secondary bands. Samples A12-02 and A61-11 in figure 
24 show only very faint bands and were therefore left out from further experiments. 
    
  Figure 24: QCPCR Plasma Samples from 1st RNA extraction.          Figure 25: QCPCR Plasma Samples from 2nd RNA extraction. 
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III.2.5 Bioanalyzer 
Figure 26 shows the Bioanalyzer result of a pure sample. One distinct, single peak represents 
the amplicon, no additional peaks other than the two ladders are visible. In comparison a less 
pure sample is shown (figure 27). As explained in chapter III.1.5 it is mostly short by-products 
which will interfere with deep sequencing, therefore the additional peaks at 499 bp and 560 bp 
were not seen as relevant. The broad base of the sample or any smaller peaks very close to the 
sample are more likely the result of denaturation of the sample than contamination. Also, the 
QCPCR samples had been pooled together in order to save costs and time (as explained in 
chapter III.1.5), so a broader and less distinct peak in this case is due to the fact that two 
samples were run together. For the rest of the Bioanalyzer results see the appendix. 
 
     Figure 26: Bioanalyzer example plasma sample A42-10. 
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     Figure 27: Bioanalyzer example plasma samples C01-15 and B35-04 QCPCR pooled. 
 
 
III.2.6 PicoGreen Quantification (Library Quantitation) 
The library was quantified using PicoGreen Quantification (see figures 28–30). After re-
measuring NS5b (see chapter II.2.3.10), all values of the samples fall within the range of the 
standard curve. As recommended in GS Junior Library Preparation Method Manual [18], the 
square of the correlation coefficient, R2, is higher than 0.98, suggesting that the results of the 
quantification are reliable. Six samples with amplicon NS3 which were originally from the first 
RNA extraction were arranged together, eight NS3 samples from the second RNA extraction and 
eight NS5b samples. This grouping was later continued at the three actual deep sequencing 
runs. 
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III.2.6.1 Results from 1st RNA extraction NS3 
 
Figure 28: PicoGreen results from first RNA extraction NS3 showing the amount of DNA of six samples from the first RNA 
extraction. 
 
III.2.6.2 Results from 2nd RNA extraction NS3 
 
Figure 29: PicoGreen results from second RNA extraction NS3 showing the amount of DNA of eight NS3 samples from the 
second RNA extraction. 
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III.2.6.3 Results from NS5b samples 
 
Figure 30: PicoGreen results showing the amount of DNA of eight NS5b samples. 
 
 
III.2.7 Bead counting 
As explained in chapter III.1.7, loading to little amount of DNA onto the plate for the deep 
sequencing run leads to good quality but low data output while too much amount of DNA 
equals poor image resolution and problems with the analysis, which is why the best amount of 
beads for the deep sequencing run was determined for each of the three runs individually. 
According the GS Junior emPCR Amplification Method Manual, an enrichment between 5% and 
20% will generate satisfactory sequencing results [19], but previous experiments had shown 
that an amount of DNA beads at the lower end of the window yields the best results. 
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III.2.7.1 Results from 1st RNA extraction NS3 
The white enriched capture beads match up with the lower line of the window on the bead 
counter, resulting in an enrichment of 5% (see figure 31). 90% of the beads, i.e. 450,000 beads 
were used for the deep sequencing run. 
 
 
 
III.2.7.2 Results from 2nd RNA extraction NS3 
White enriched beads show in the lower half of the window, resulting in an enrichment of          
8–10% (see figure 32). 50% of the beads were used for the run. 
  
 
Figure 31: Enrichment NS3 samples from first RNA extraction showing the white beads on the bottom 
of the 1.7ml tube matching up with the lower line of the window of the bead counter, corresponding 
to about 5% enrichment or 500,000 beads. 
Figure 32: Enrichment NS3 samples from second RNA extraction showing enriched beads approximately 
covering the lower half of the window, representing an enrichment of 8–10% or 800,000 to 1,000,000 
beads. 
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III.2.7.3 Results from NS5b samples 
This time, white enriched beads show slightly under the lower line of the window, resulting in 
an enrichment of 4% (see figure 33). All of the beads were used for the deep sequencing run. 
 
 
 
 
III.2.8 Numbers from the run 
As explained in chapter III.1.8, Raw Wells means the number of all detected signals on the plate 
during the run, while Key Pass Wells equals all the Raw Wells starting with a valid key sequence. 
Passed Filter Wells are the total of reads which pass all of the program’s filters. As mentioned, 
GS Junior recommends the ratio of Passed Filter Wells / Key Pass Wells to be higher than 25–
50% and Key Pass Wells / Total Raw Wells to be higher than 90%. Also, the higher the number of 
reads per amplicon, the more likely a minor variant at a very low percentage actually represents 
a real mutation and not just sequencing error. 
Figure 33: Enrichment NS5b samples with beads showing slightly under the lower line of the window, 
meaning about 4% or 400,000 of enriched capture beads were collected. 
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III.2.8.1 Results for the 1st deep sequencing run 
The number of reads per amplicon ranged between 10,080 and 19,708. Passed Filter Wells/ Key 
Pass Wells = 0.55 or 55%.  KeyPassWells/totalRawWells is 0.96 or 96%, as recommended by GS 
Junior Data Analysis Terminology and Benchmarks [25] (see table 59). 
 
TCAG (Library) Region Total 
Raw Wells 185,623 185,623 
Key Pass Wells 178,408 178,408 
Passed Filter Wells 97,812 97,812 
Total bases 43,501,586 43,501,586 
Average Read Length 444.75 444.75 
Length Std Deviation 28.02  
Longest Read Length 688 688 
Shortest Read Length 40 40 
Median Read Length 447.0 447.0 
Modal Read Length 447.0 447.0 
      Table 59: Numbers from first deep sequencing run. 
 
III.2.8.2 Results for the 2nd deep sequencing run 
For the second run, the number of reads per amplicon ranged between 5,001 and 13,019. 
Passed Filter Wells/ Key Pass Wells = 0.45 or 45%, as recommended. 
KeyPassWells/totalRawWells is 0.95 or 95%, as recommended (see table 60). 
 
TCAG (Library) Region Total 
Raw Wells 160,878 160,878 
Key Pass Wells 153,492 153,492 
Passed Filter Wells 69,033 69,033 
Total bases 30,676,853 30,686,853 
Average Read Length 444.38 444.38 
Length Std Deviation 27.29  
Longest Read Length 511 511 
Shortest Read Length 47 47 
Median Read Length 447.0 447.0 
Modal Read Length 447.0 447.0 
       Table 60: Numbers from second deep sequencing run. 
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III.2.8.3 Results for the 3rd deep sequencing run 
The number of reads per amplicon ranged between 3,848 and 7,477. Unfortunately, for the 
amplicon with the lowest number of reads this does not allow any conclusions on variants lower 
than 1.3%. Passed Filter Wells/ Key Pass Wells = 0.66, or 66%. A little low is 
KeyPassWells/totalRawWells: 0.89 or 89% (see table 61). But with a very high number of total 
filter passed reads, it is very close to the recommended percentage. 
 
TCAG (Library) Region Total 
Raw Wells 81,710 81,710 
Key Pass Wells 72,463 72,463 
Passed Filter Wells 47,951 47,951 
Total bases 21,658,263 21,658,263 
Average Read Length 451.67 451.67 
Length Std Deviation 20.36  
Longest Read Length 819 819 
Shortest Read Length 45 45 
Median Read Length 453.0 453.0 
Modal Read Length 453.0 453.0 
     Table 61: Numbers from third deep sequencing run. 
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III.2.9 Deep sequencing results 
In three deep sequencing runs, a total of 16 samples was analyzed, there from eleven with 
genotype 1a and five with genotype 1b. 14 samples (11x 1a and 3x 1b) were sequenced for 
NS2/NS3p, looking for Q80K amongst other variants. Eight samples were sequenced for NS5b 
(three 1a and five 1b) looking for C316 and other variants. Three 1a samples and three 1b 
samples were sequenced for variants both in the NS2/NS3p and NS5b region (see table 62). 
 samples 1st run 2nd run 3rd run 
Ge
no
typ
e 1
a 
A24-10 
NS
2/
NS
3p
   A42-10   
A57-10  NS5b A85-03  
A93-03   
A94-01   
B05-08  
NS
2/
NS
3p
  
B49-03   
B51-01   
B84-01   
C01-15   
Ge
no
typ
e 1
b A76-05    
B35-04   
B37-03  
B57-01  
C06-01   
         Table 62: Plasma samples sequenced for NS2/3 and NS5b. 
Ten out of 14 samples sequenced for the NS3 region showed the RAV Q80K. At nine of them, 
the percentage of viral copies with Q80K within one patient’s plasma was very high (between 
97.86% and 100%). One of them was genotype 1b. One sample showed both variants Q80K (at 
84%) and Q80R (16%) (see appendix). 
One of the 1a samples positive for Q80K showed also the RAV V36L at 48%.  
Only one of the eight samples sequenced for NS5b showed the mutation C316N at a very low 
percentage (1.2%). But with a read number of 3848 for this amplicon this equals 46 reads for 
the mutation, which according to 454 GS Junior Sequencing System Guidelines is probably 
coincidental, as the threshold for a mutation to be considered real is 50 reads [22]. 
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34 variants were found in NS2, whereas 58 showed up in NS3. However, neither NS2 nor NS3 
were sequenced completely.  
Q80K was among the three most prevalent variants, together with Q199R in the NS2 region and 
T40A in NS3. 
Numerous other variants were found at each run in NS2, NS3 and NS5b without resulting in any 
aminoacid changes and therefore representing only silent mutations or polymorphisms. Some 
of them, however, are located at positions which typically show clinically relevant mutations like 
positions 36, 43, 54 and 55 in NS3 (see appendices 2, 3 and 4). 
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IV. Discussion 
IV.1 Mutant Mix 
IV.1.1 Analysis of the run 
According to 454 GS Junior Sequencing System Guidelines [22], a mutation should appear 50 
times as a minimum cut-off in order to decide that it is real and not just coincidental, due to 
sequencing error.  For instance, for an amplicon with 5000 reads, 1% and higher can be 
considered a real mutation. For this thesis, all numbers below this threshold were left out of the 
analysis. 
According to GS Junior Data Analysis Terminology and Benchmarks [25], 
totalPassFiltering/totalKeyPass should be above 25–50% and the fraction of 
KeyPassWells/totalRawWells is recommended to be higher than 90%. The numbers from the 
Mutant Mix deep sequencing run match the criteria (see section III.1.8). 
 
 
IV.1.2 Deep sequencing accuracy 
The aim of the Mutant Mix Experiment was to find a threshold for RNA input at which deep 
sequencing results are still reliable. The numbers show that mutants can still be picked up from 
RNA added at a quantity of only 0.5 pg/µl even for the mutant added at the lowest percentage 
(0.3%). 
In summary, we found that as long as a sample shows up on a PCR-gel after amplification, even 
as a faint band only, deep sequencing numbers still match the percentages from the input, 
within error, and can therefore be considered accurate. 
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IV.2 Plasma samples 
IV.2.1 Analysis of the run 
The recommendations for amplicon run results are described in section III.2.8. The numbers 
from the plasma samples deep sequencing run match the criteria, except for the 3rd deep 
sequencing run where KeyPassWells/totalRawWells are only 0.89 or 89%. However, this number 
is right below the threshold, and is therefore considered to be sufficiently close to the 
recommended percentage, as ultimately we still obtained a very high number of total filter 
passed reads. The raw wells from the 3rd run are low compared to the two other runs (only half 
of the raw wells from the 2nd run). As a result, the number of reads is also low for some of the 
amplicons in the 3rd run. As described in section IV.1.1, all variants below the threshold for reads 
to be considerable are hence excluded from the analysis and also do not show up in the table in 
the appendix.  
Major cross-contamination between the samples can be ruled out by simply aligning deep 
sequencing results from each patient and comparing variants in each sample to the others (see 
lists of variants in the appendix).  
Insertions which show up in the deep sequencing results are most likely due to sequencing 
error, as the 454 has a tendency to show insertions on homo-polymeric stretches and are 
therefore left out of the analysis. 
At some positions, the plasmid control sequence differs from the reference sequence. This is 
simply explained with the high genetic variability of HCV where at those positions the plasmid 
sequence does not match the reference sequence used. 
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 IV.2.2 Discussing the method 
Errors can occur throughout the whole experimental setup, from the RNA extraction to the 
actual sequencing. Cross-contamination can be ruled out as described previously. Deep 
sequencing is a rather expensive and time-consuming method, limiting the number of samples 
that can be processed. However, with a small number of samples like in this thesis, a selection 
bias is prone to happen.  
But in view of the results from the Mutant Mix Experiment, deep sequencing proves to qualify 
as a method for investigating plasma samples for RAVs, even for patients with low viral loads. 
Unlike for the paper from Jabara et al. [8] (see IV.2.3), for this thesis a Lib-A emPCR 
Amplification Kit was used. The advantages of bidirectional sequencing with the use of two 
primers, compared to the unidirectional sequencing with the Lib-L Kit are that it provides higher 
accuracy. Determining whether a variant is valid or not can be easier when it shows up in both 
forward and reverse reads independently. However, unidirectional sequencing can cover a 
wider part of the genome and therefore screen for more variants at once [22]. 
A systematic review from 2017 compares several currently available HCV sequencing methods 
for RAVs, in order to find the ideal protocol, describing strengths and limitations of current 
methods. The ideal method is described as a full length, pan-genotypic, cost effective method 
with a low limit of detection. However, no method matching all of those features was found 
[26].  
In order for the protocol in this thesis to be generally applicable, multi- or pan-genotypic 
primers would have needed to be used. In this case, the primers were matching genotype 1a 
and 1b samples. Other genotypes, however, were not included. But, with the extensive genetic 
variability of the Hepatitis C virus, it is difficult to find the ideal method of sequencing. Only a 
small number of primers generate amplicons which cover all regions of interest but at the same 
time are still applicable to more than one genotype. Template-independent amplification 
methods which can provide multi-genotypic and full length sequencing at the same time “have a 
high limit of detection” [26].  
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IV.2.3 Resistance-associated variants (RAVs) in NS2/3 and NS5b 
The surprisingly high prevalence of Q80K in plasma samples included in this thesis (10 out of 14 
samples which had been sequenced for NS3 show the polymorphism) raises several questions: 
Is this high prevalence and high frequency similar to findings from other experiments or 
studies? Is it due to the fact that the Hepatitis C Virus in HCV/HIV-co-infected patients is more 
likely to mutate? How significant is the impact of the polymorphism Q80K on a treatment that 
includes simeprevir? And in consequence of this, should patients be screened for Q80K and 
other RAVs prior to treatment with DAAs? 
In the paper “Hepatits C virus NS3 sequence diversity and antiviral RAV frequency in HCV/HIV 
co-infection”, published on 4 August 2014, around the same time as the experiments for this 
thesis were conducted, 20 monoinfected HCV-positive patients were compared to 20 HIV/HCV-
co-infected patients [8]. All 40 of them had been deep sequenced for Q80K as well as other 
resistance-associated variants located in NS3. A total number of 40 subjects might not be 
completely sufficient for a sound statistical analysis. However, the results were similar to the 
findings in this thesis: 17 out of the 40 subjects showed the variant Q80K. In 11 of the 
monoinfected and in 6 of the co-infected patients, Q80K was present with a frequency of at 
least 99% each. 
Unlike the study by Jabara et al., for this thesis patients infected with genotype 1a and 1b were 
included, but only HCV/HIV co-infected subjects. 
With only 3 samples of genotype 1b screened for Q80K there is unfortunately not enough data 
to make a statement on subtype predisposition for the aminoacid change. When consulting the 
literature, however, it seems that this polymorphism is much more prevalent in subtype 1a than 
it is in 1b. The article on a meta-analysis of Q80K prevalence in 3349 HCV genotype 1-infected 
patients “Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in 
the European region” comes to the conclusion that Q80K is present at approximately 7.5% 
overall. The percentages vary, depending on subtype and region. Subtype 1a shows the variant 
Q80K at 19.8%, 1b only at 0.5% [27]. However, if HCV/HIV-co-infection has an impact on RAV-
rates was not investigated here.  
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A clinical study published by Enass A. Abdel-Hameed et al. in 2017 finds RAVs prevalent in 73.3% 
of HCV/HIV co-infected subjects. Among them, Q80K showed the highest prevalence: 46.7%, 
which might suggest that a co-infection with HIV leads to a higher mutation rate of the hepatitis 
C virus. After a 12 week course with PegIFN/ribavirin, RAV rates went up to 83.3%, with Q80K at 
56.7%, indicating that non DAA treatments also pressure the virus to develop mutations [28]. 
Another possible explanation for the very high prevalence of RAVs, especially Q80K in this study 
could be that the authors had investigated only a local group of infected patients. Interaction 
between the individuals, i.e. the virus being transmitted from one subject to others within the 
study, could lead to a founder effect. Although the authors do not explicitly tell how close the 
30 subjects were, all of them had been previously enrolled in a clinical trial with broad 
geographic representation [29]. 
An article from 2016 investigating the prevalence of RAVs in the NS3 region in patients infected 
with HCV genotype 1a found the prevalence of Q80K in HCV/HIV co-infected individuals to be 
12.9% while it was 9.6% in HCV mono-infected subjects. This supports the theory that HCV/HIV 
co-infection could be one reason for the high prevalence of Q80K in samples from this thesis 
[30]. 
According to another article, the RAVs Q80K and Q80R show up in less than 10% of treatment 
failure patients but provide 420-fold respectively 305-fold the normal resistance to simeprevir 
when combined with R155K [15]. However, patients with the RAV Q80K still have high SVR rates 
of 92% when treated with a combination of simeprevir plus sofosbuvir with or without ribavirin. 
Only when other negative predictive factors are present at the same time (previous treatment, 
liver cirrhosis) Q80K leads to (significantly) worse treatment results [31, 32]. 
Normally, pre-existing resistance-causing mutations in the genome of bacteria or viruses exist at 
low levels until the beginning of treatment, when they become dominant due to their selective 
advantage [8]. The only way to predict the outcome of a therapy with DAAs would be to screen 
for those mutations using a method which can detect mutants at very low percentages, such as 
deep sequencing. 
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More rarely, resistance-associated variants represent not just a minor fraction of the genome 
but are in fact already dominant in treatment-naïve patients, in which case they could easily be 
picked up by population sequencing as well.  
 
 
IV.2.4 Implication 
With the introduction of the first DAAs emerged the hope for a cure of HCV-infected patients 
with “short treatment duration and acceptable adverse events” [13]. During the following years 
research dealt with reducing adverse side effects by omitting IFN from the treatment. The 
COSMOS randomised study investigated in 2014 a completely IFN-free regimen by treating 167 
patients with chronic HCV with either a combination of simeprevir and sofosbuvir only, or RBV 
plus the two DAAs. As SVR of 92% were achieved after 12 weeks in 154 patients while serious 
adverse events were only seen in 2% of the patients, this IFN-free treatment seems to be both 
“efficacious and well tolerated” [14]. Guidelines of the DGVS (Deutsche Gesellschaft für 
Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten), member of the AWMF 
(Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachangestellten) from 2015 
already do not approve IFN-based regimes as standard therapy anymore [33]. The latest 
guidelines from 2018 recommend several IFN-free, DAA-based regimes. As for an HCV/HIV co-
infection, treatment is recommended to be the same as for monoinfected patients [31].  
Resistance-associated variants like Q80K and C316N can theoretically cause regimens to fail, 
especially when DAAs play a main part in this treatment. At the beginning of DAAs it hence 
looked like important tasks for future research were to further determine the prevalence and 
frequency of RAVs as well as their total impact on treatments with DAAs.  
In comparison: with HIV, general screening for RAVs before starting treatment is more common. 
The German AIDS Society (Deutsche AIDS Gesellschaft e.V.) for instance recommends in its 
guidelines from 2017 to do a genotypic test on every HIV infected patient for resistance causing 
mutations before starting treatment [34]. 
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However, new drugs for HCV are admitted every year and today regimens which are 
independent of the genotype and of a pre-treatment analysis exist. 
The latest AWMF guidelines for treatment of Hepatitis C Virus infection from 2018 list several 
different combinations of DAAs as effective IFN-free regimens, amongst them the combination 
of simeprevir and sofosbuvir plus ribavirin for genotypes 1 and 4, but not as first line therapy. 
Some of those regimens like the 12-week-course of sofosbuvir and velpatasvir even show SVR 
rates of at least 95% overall (with the exceptions of 91% SVR in genotype 3-infected patients 
with compensated liver cirrhosis and 90% SVR in genotype 3-infected patients with prior 
treatment) for all genotypes 1 to 4, in patients with or without cirrhosis, and without prior 
screening for RAVs and are therefore recommended for first and re-therapy for all genotypes 
mostly independent of RAVs [31]. 
As for the combination of simeprevir plus sofosbuvir: SVR rates drop from 92% in patients with 
liver cirrhosis without Q80K to only 74% in patients with both liver cirrhosis and Q80K according 
to the OPTIMIST-2 study [32]. 
The AWMF guidelines recommend pre-treatment viral resistance analysis for three scenarios 
only: 
- a NS5A resistance analysis should be conducted beforehand when treating with the 
second generation NS3 protease inhibitor grazoprevir and NS5A inhibitor elbasvir for 12 
weeks for patients infected with HCV genotype 1a 
- Patients infected with HCV genotype 3 can undergo NS5A resistance analysis before 
starting treatment with daclatasvir and velpatasvir in combination with sofosbuvir  
- After treatment with DAAs failed, patients should have viral resistance analysis in order 
to choose the right regimen for re-therapy [31]. 
Although it is not determined whether this pre-treatment analysis should be conducted via next 
generation sequencing or population sequencing, the authors postulate that only RAVs at a 
percentage of 15% or higher (a level which can be detected by population sequencing) have 
significant influence on SVRs [31, 35]. 
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One major problem of DAAs remains their expensiveness. According to the free educational 
website from the University of Washington “Hepatitis C Online”, a 12-week course with 
simeprevir costs $66,000, while an interferon-free regimen with simeprevir (Olysio) plus 
sofosbuvir (Sovaldi) for 12 weeks, as recommended in the COSMOS-study costs approximately 
$150,000 (depending on exchange rates about 150,000€). A 12 week course of sofosbuvir plus 
velpatasvir as recommended by the AWMF guidelines costs about $75,000. However, that is 
about 300 times higher than the estimated production costs [36]. 
As for Germany: in 2015, sofosbuvir provider Gilead and german health insurance companies 
(GKV) agreed on a price for a 12 week course of sofosbuvir of 43,562€, which put the real costs 
as sold by pharmacies (Apothekenverkaufspreis) in the end at around 53,000€ [37, 38]. Since 
then, not much has changed. In 2017 the association “Ärzte ohne Grenzen” together with 
organisations from 17 other countries objected in front of the European Patent Office to 
Gilead’s patent for sofosbuvir, arguing that the costs for the drug are unreasonably high. In 
September 2018 the European Patent Office decided against them. In consequence, Gilead 
keeps its patent for sofosbuvir [39]. 
Prices for other DAAs can sometimes be difficult to find out, since they are determined in 
negotiations between insurance companies and providers.  
Presuming that pre-treatment analysis is conducted via population sequencing, costs are about 
260€, corresponding to the costs for genotype resistance sequencing of HIV according to the 
website of “Kassenärztliche Bundesvereinigung” [40]. 
As a very rough estimation, the screening of 203 patients for the variant Q80K would cost as 
much as treating one patient with a 12 week course of sofosbuvir.  
The critical question in this matter is therefore, how cheap new therapies (for example 
simeprevir/sofosbuvir with or without RBV) would have to be so that screening for RAVs does 
not pay off.   
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If 1000 patients were treated, without previous screening, with a combination of DAAs like for 
example simeprevir plus sofosbuvir with or without RBV, costs for this regime would be 1000 
times x. 
If a pre-treatment screening with population sequencing was taken into account, costs would 
rise up to 260€ + x, 260€ being the costs for the pre-treatment analysis of one patient. Assuming 
that the prevalence of Q80K is only 7.5% [27], 75 out of 1000 patients would benefit from 
another regime, not containing simeprevir. Meanwhile, the rest of the 925 patients without 
Q80K still would have been screened and then treated. Their costs would hence be 260€ + x. 
      1000 < 75 ⋅ 260€ + 925 ⋅ 260€ +  
⇔ 1000 < 19500 € + 240500 € + 925 
     ⇔ 75 < 260000 € 
          ⇔  < 3467 € 
With a higher prevalence of Q80K, the result for x would be even lower. 
Only if the treatment costs for simeprevir plus sofosbuvir with or without RBV were lower than 
3,467€, screening for Q80K with population sequencing would not pay off. Of course, the 
current costs are about 10 to 50 times higher and it does not look like as if they are going to 
drop any time soon.  
However, as previously mentioned, literature shows that the prevalence of Q80K only seems to 
result in treatment failure when other negative predictive factors such as liver cirrhosis are 
present [31, 32, 35]. 
Meanwhile, the costs for sequencing are in free fall. According to an article from 2009 on 
Spiegel Online, sequencing the whole human genome at that time cost $48,000 [41]. The 
Assman-Stiftung describes on its website costs for whole genome sequencing of only 1000€ in 
the year 2012 [42]. And in 2017 the American company Illumina presented the new sequencer 
“NovaSeq” and promised on its website the $100 genome in the future [43]. 
As for this study, Q80K shows up at either close to 0% or almost 100% (all or nothing). As such it 
could be easily detected by population sequencing as well [31, 35]. Furthermore, any variant 
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with a frequency lower than 15% within the viral population does not seem to significantly 
impact treatment success and should therefore not influence a treatment decision [35, 26] 
During the time of the experiments for this study, it looked like population sequencing was 
maybe a cheaper, but definitely a more practical method since most labs are provided with PCR 
machines while next generation sequencing machines were still highly expensive in purchase 
and maintenance. Today, next generation sequencing has become much more accessible and its 
costs have decreased. But even if screening is performed with population sequencing and Q80K 
does not show up, deep sequencing for its presence as a minor variant still remains an option. 
NGS also allows for a closer look on how exactly the virus reacts to a treatment with DAAs 
especially in patients with treatment failure or relapse, as demonstrated by Bonsall et al. in 
2018, where the authors hypothesise that “the selective pressures exerted by modern 
treatments, coupled with the ability of HCV to mutate may have a significant role in shaping the 
future HCV pandemic” [44].    
In conclusion, while population sequencing seems to be the preferable method for genotypic 
resistance testing, the significance of next generation sequencing lies mostly in the analysis of 
patient samples during treatment failure, in order to investigate the exact order of selection 
within certain viral populations.  
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Abstract 
Hepatitis C Virus infection affects more than 170 Million people worldwide. With the 
introduction of direct acting antivirals (DAAs) into therapy in 2011, treatment of chronic 
hepatitis C infection has experienced major improvement showing less side-effects and higher 
treatment success rates compared to early hepatitis C therapy consisting of a combination of 
only pegylated interferon-alpha (pIFN-alpha) and ribavirin (RBV). However, as with every new 
antiviral or antibiotic therapy, resistance-associated variants emerge with treatment. Some 
resistance-associated polymorphisms are even found to be pre-existing in treatment-naïve 
patients. Unfortunately, DAAs also remain very expensive, which limits the options on a world-
wide use and interferon-free regimens.  
Because of similar pathways of infection, HCV/HIV co-infection is not uncommon but 
complicates treatment, leads to higher complication rates and possibly a higher prevalence of 
resistance-associated variants (RAVs).  
For this thesis, the main goals were to establish a screening method for RAVs in plasma from 
HCV/HIV co-infected patients with deep sequencing and to investigate deep sequencing 
accuracy especially at low RNA input (low viral load) and low prevalence of RAVs within one 
patient.  
A serial dilution of a mix of in vitro transcribed mutants S122R, R155K, D168V and a wild-type 
was sequenced. It was found that mutants can still be picked up when RNA is added at a 
quantity of only 0.5 pg, even for the mutant added at the lowest percentage (0.3%). In 
conclusion, deep sequencing proves to qualify as a method for investigating plasma samples for 
resistance-associated variants, even for patients with low viral loads. 
Afterwards, it was shown in an experiment with few samples that screening for RAVs using deep 
sequencing or population sequencing prior to treatment with DAAs would make sense, 
especially given the high costs for DAAs. Therefore, 16 plasma samples from HCV/HIV co-
infected, treatment-naïve patients were screened for pre-existing variants in the NS3 and NS5b 
regions of the Hepatitis C Virus using deep sequencing. Patients were infected with HCV 
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genotypes 1a and 1b. Especially the two resistance-associated polymorphisms Q80K in NS3 and 
C316N in NS5b were of interest. Q80K provides a certain resistance against simeprevir, while 
C316N is associated with resistance against polymerase-inhibitors like sofosbuvir. 
A number of genetic variations of the original consensus sequence were found. As for Q80K, the 
polymorphism was found in 10 out of 14 samples. Each time, the percentage of viral copies with 
Q80K within one patient’s plasma was very high (> 97% in 9 samples, 84% in 1 sample). C316N 
however, was only present at a very low percentage (1.2%) in one out of 8 samples. 
With such high percentages of variants, screening with population sequencing would be 
effective enough. The significance of deep sequencing then probably lies in the analysis of 
patient samples during treatment failure, in order to investigate the exact order of selection 
within certain viral populations. 
 
However, the number of samples in this study is too low to make a valid statistical statement. 
More studies with higher numbers of samples would be necessary to support this theory. 
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Zusammenfassung 
Weltweit sind mehr als 170 Millionen Menschen mit dem Hepatitis C Virus infiziert. Dank der 
2011 auf den Markt gekommenen direct acting antivirals (DAAs) hat sich die Therapie von 
Patienten mit chronischer Hepatitis C deutlich verbessert. Geringere Nebenwirkungen und 
höhere Erfolgsraten zeigen sich im Vergleich mit der herkömmlichen Therapie bestehend aus 
der Kombination von pegyliertem Interferon-alpha (pIFN-alpha) und Ribavirin (RBV). Wie bei 
jeder neuen antiviralen oder antibiotischen Therapie entwickeln sich allerdings  auch im 
Hepatitis C Virus Resistenzen vermittelnde genetische Varianten oder Mutationen, sogenannte 
resistance-associated variants (RAVs). Manche resistenz-vermittelnde Polymorphismen sind 
sogar bereits vor Therapiebeginn existent. Leider ist die Therapie mit DAAs nach wie vor sehr 
teuer, wodurch die Möglichkeiten einer weltweiten Nutzung sowie die Aussicht auf Interferon-
freie Therapien begrenzt werden. 
HCV und HIV haben ähnliche Übertragungswege, weswegen Koinfektionen keine Seltenheit 
sind. Allerdings kompliziert eine HCV/HIV-Koinfektion die Behandlung, führt zu höheren 
Komplikationsraten und möglicherweise auch zu einer höheren Prävalenz an RAVs. 
Die beiden Hauptziele dieser Arbeit waren zum einen, die technische Durchführung eines 
Screenings auf RAVs mittels Deep Sequencing zu etablieren, und zum anderen die Genauigkeit 
von „Next-Generation-Sequencing“ (NGS) besonders bei niedriger Viruslast und niedriger 
Prävalenz von RAVs im Patienten zu untersuchen. 
Hierfür wurde eine Serienverdünnung von einem Mix aus in vitro transkribierten Mutanten 
S122R, R155K, D168V und dem Wildtyp sequenziert. Es wurde festgestellt, dass Mutanten auch 
dann noch detektiert werden, wenn nur 0,5 pg RNA zugegeben wurden. Selbst der Mutant mit 
dem geringsten Anteil am Mix (0,3%) zeigte sich in den Ergebnissen. Zusammenfassend gesagt 
beweist sich NGS als eine gute Methode um Plasmaproben auf RAVs zu untersuchen, selbst bei 
Patienten mit niedriger Viruslast. 
Anschließend wurde an einer geringen Anzahl an Proben gezeigt, dass ein routinemäßiges 
Screening auf RAVs mittels NGS oder Population Sequencing sinnvoll wäre, besonders aufgrund 
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der hohen Kosten für DAAs. Es wurden 16 Plasmaproben von HCV/HIV-koinfizierten, bisher 
nicht behandelten Patienten auf präexistente RAVs in den Regionen NS3 und NS5b gescreent. 
Die Patienten waren mit HCV-Genotyp 1a und 1b infiziert. Hauptaugenmerk lag auf den beiden 
Polymorphismen Q80K in NS3 und C316N in NS5b. Durch Q80K erlangt das Virus eine gewisse 
Resistenz gegen Simeprevir, wohingegen C316N mit einer Resistenz gegen Sofosbuvir assoziiert 
ist.  
Es wurden eine Reihe von genetischen Abweichungen von der jeweiligen Konsensussequenz 
gefunden. In 10 von 14 Proben fand sich Q80K, davon neunmal zu über 97% und einmal zu 84%. 
C316N hingegen fand sich nur in einer von acht Proben, zu nur 1,2%.  
Bei solch hohen Anteilen von Virusvarianten wäre ein Sequenzieren mit Population Sequencing 
völlig ausreichen, der Stellenwert von NGS läge dann vermutlich in einer Feinanalyse von 
Patientenproben, die während eines Therapieversagens gewonnen werden, um die genaue 
Abfolge der Selektion bestimmter Viruspopulationen darzustellen. 
Für eine statistisch belastbare Aussage ist die Probenzahl allerdings deutlich zu gering und 
weitere Studien mit größeren Patientenzahlen sind vonnöten um diese Aussage zu 
unterstützen. 
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Appendix:  
 
Heat map: presence and relative frequency of RAVs 
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Heat map part 2 
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List of variants first deep sequencing run
 
reference sequence Re.1a.US.77.H77
genotype
Number of reads 13713 19708 12900 10653 14097 10080 15518
Variant
aminoacid 
position in 
NS2/3
A24-10 % A42-10 % A57-10 % A85-03 % A93-03 % A94-01  % WT control  (H77 plasmid) % variant original codon new codon
576:C/T 192 0 0,67 0 0,15 0 0 0 P192 silent CCC CCT 576
582:T/C 194 99,88 99,12 0,29 4,57 100 0 0 S194 silent TCT TCC 582
585:C/T 195 0 1,06 0 0 0 0 0 A195 silent GCC GCT 585
588.5:-/G 196,1666667 1,64 0 0 0 0 0 0 588,5
588:T/C 196 45,9 0 99,59 100 0 0 0 R196 silent CGT CGC 588
589.5:-/C 196,5 0,98 0 0 0 0 0 0 589,5
589:A/C 196,3333333 0,14 0 0 7,59 0 0 0 R197 silent CGG 589
590:G/A 196,6666667 0 1,52 99,67 0 0 0 0 R197K AAG 590
590:G/C 196,6666667 0,77 0 0 0 0 0 0 R197T ACG 590
592:G/C 197,3333333 0,42 0 0 0 0 0 0 G198R CGC 592
594:C/G 198 0,42 0 0 0 0 0 0 GGG 594
594:C/T 198 0 1 0 0 0,56 0 0 GGT 594
595-596:CA/-- 1 0 0 0 0 0 0 595-596
595:C/A 198,3333333 0 0 0 0 0,72 0 0 Q199K AAG 595
595:C/G 198,3333333 0,61 0 0 0 0 0 0 Q199E GAG 595
596:A/- 198,6666667 1,53 1,2 0 0,79 0 0 0 Q199 deletion C-A 596
596:A/G 198,6666667 97,63 98,51 100 99,21 99,67 100 0 Q199R CGG 596
597:G/A 199 0 0 0 21,18 0 99,6 0 Q199 silent CAA 597
597:G/C 199 0,42 0 0 0 0 0 0 Q199H CAC 597
599.5:-/C 199,8333333 0,5 0 0 0 0 0 0 599,5
599:A/G 199,6666667 0,42 0 0 0 0 0 0 E200G GAG GGG 599
600.5:-/G 200,1666667 0,69 0 0 0 0 0 0 600,5
600:G/- 200 1,31 0 0 0 0 0 0 E200 deletion GA- 600
600:G/A 200 44,56 0,71 0 0 0 0 0 E200 silent GAA 600
601.5:-/A 200,5 0,69 0 0 0 0 0 0 601,5
601:A/G 200,3333333 0 7,08 0 0 0 0 0 I201V GTA 601
602:T/C 200,6666667 0 0,33 0 0 0 0 0 I201T ACA 602
604:C/T 201,3333333 99,68 1,37 0,67 1,09 0 0 0 L202 silent CTG TTG 604
609:T/C 203 100 2,56 100 99,7 99,58 100 0 L203 silent CTT CTC 609
612:G/A 204 0 98,95 99,81 95,03 100 99,86 0 GGA 612
612:G/C 204 0 0,39 0 0 0 0 0 GGC 612
612:G/T 204 100 0 0 0 0 0 0 GGT 612
615:A/C 205 0,47 0,92 0 0 0 0 0 CCC 615
615:A/G 205 98,98 0 0 100 100 100 0 CCG 615
615:A/T 205 0 99,08 0 0 0 0 0 CCT 615
618:C/T 206 0 4,76 0 0 0 0 0 A206 silent GCC GCT 618
621:C/T 207 0 99,84 98,66 100 19,66 100 0 D207 silent GAC GAT 621
623:G/A 207,6666667 0 0,45 0 0 3,91 0 0 G208 E GAA 623
624:A/C 208 0 0 11,23 0 0 0 0 GGC 624
624:A/G 208 0 0,72 0,36 10,44 1,11 0 0 GGG GAG -> E (1 and 3) 624
625:A/G 208,3333333 0 0 0 0,19 100 0 0 M209V GTG 625
626:T/C 208,6666667 0 0 0 0 0,49 0 0 M209T ACG GCG -> A (1 and 2) 626
629:T/A 209,6666667 0 0 0,46 0 0 0 0 V 629
629:T/C 209,6666667 0 0,61 99,54 0 0 0 0 V210A GCC 629
630:C/T 210 0 0,7 0 0 0 0 0 V 630
633:C/T 211 100 90,4 0 0 0,46 0 0 S211 TCC TTC 633
634:A/C 211,3333333 0 0,44 0 0 0 0 0 K212 634
635:A/G 211,6666667 0,36 0,83 0 0 0,42 0 0 K212 635
636:G/A 212 0 1,77 0 0 0 0 0 K212silent AAA 636
639:G/A 213 0 0,14 0 0,39 0 0 0 G213 GGG 639
643:A/C 214,3333333 0 0 0 0,38 0 0 0 R215 AGG 643
646:T/C 215,3333333 0 0,53 0,93 2,2 0 0 0 L216S TTG TCG 646
649:C/T 216,3333333 0 0 0 0 77,11 0 0 L217 silent TTG 649
651:G/A 217 0 0 0 0,97 0 0,58 0 L 651
651:G/C 217 99,37 0 0 0 0 0 0 L217 silent CTC 651
651:G/T 217 0,63 0 0 0 0 0 0 L 651
654:G/A 1 0 0,56 0 34,32 0 0 0 GCA 654
654:G/T 1 0 0 0 0 0,67 0 0 GCT 654
657:C/T 2 0 55,19 0,14 0 0,34 53,41 0 P2 silent CCC CCT 657
660:C/T 3 0 5,53 0 0,42 0,12 56,67 0 I3 silent ATC ATT 660
663:G/A 4 0 0 0 0,61 0 0 0 T4 silent ACG ACA 663
666:G/A 5 0 0,92 0 0 0,42 0 0 A5 silent GCG GCA 666
669:C/T 6 0 0,36 0,48 99,28 0,65 99,86 0 Y6 silent TAC TAT 669
672:C/T 7 0 96,61 0,6 0 0 0 0 A7 silent GCC GCT 672
681:G/A 10 92,42 0 0 99,86 0 99,64 0 T10 silent ACG ACA 681
684:A/G 11 96,85 98,83 100 99,69 100 100 0 R11 silent AGA AGG 684
688:C/A 12,33 0 0 0 0 0,28 0 0 L13I CTC ATC 688
690:C/T 13 17,92 0 0 34,73 0 0 0 L13 silent CTC CTT 690
691-693:CTA/TNG 0 0 0 98,79 0 99,05 0 TTG
691:C/T 13,33 0 0,65 0 98,79 0,2 99,19 0 TTA 691
693:A/G 14 0 0 0 99,48 0 99,86 0 CTG TTG -> L silent 693
696:G/A 15 0 0,3 0 48,74 0 99,33 0 G15 silent GGG GGA 696
699:T/C 16 0 9,33 100 99,86 0,14 100 0 C16 silent TGT TGC 699
700:A/G 16,33 0 0,52 0 0 0 0 0 I17V ATA GTA 700
705:C/A 18 0 0 0 0,95 0 0 0 ATA 705
705:C/T 18 0 0,35 0 98,18 20,08 99,47 0 ATT 705
711:C/T 20 0 0,5 0 0 1,21 0 0 S20 silent AGC AGT 711
712:C/T 20,33 0 1,88 0 99,86 0 100 0 L21 silent CTG TTG 712
717:T/C 22 0 1,61 99,71 94,73 100 100 0 T22 silent ACT ACC 717
720:C/T 23 0 0,49 0 0 0 0 0 G23 silent GGC GGT 720
723:G/A 24 0 99,24 98,67 2,55 0 0 0 R24 silent CGG CGA 723
726:C/T 25 0 1,64 0 0 0,14 0 0 D25 silent GAC GAT 726
728:A/G 25,67 0 0 0 0 6,32 0 0 K26R AGA 728
729:A/G 26 100 6,21 0 0,54 0 0,3 0 K26 silent AAG 729
732:C/T 27 0 0,58 0 27,14 0 0 0 N27 silent AAC AAT 732
735:A/G 28 0 1,77 0 99,48 100 99,85 0 Q28 silent CAA CAG 735
744:T/C 31 0 0,9 0 0,35 0,86 0 0 G31 silent GGT GGC 744
747:G/A 32 0 0,48 0 0 0 0 0 E32 silent GAG GAA 747
748:G/A 32,33 95,62 98,95 0 0 0 0 0 V33I ATC 748
750:C/T 33 0 0,92 0 88,83 0 99,47 0 V33 silent GTT 750
753:G/A 34 0 0,34 0 0 0 0 0 Q34 silent CAG CAA 753
CTG
L14 silent
ATC
AAA
GTC
CTA
GCG
AGG
G198 silent
GGC
CAG
ATA
GAG
ATG
GGGG204 silent
CCAP205 silent
G208 silent GGA
GTC
AAG
all samples genotype 1a
A1 silent
I18 silent
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754:A/G 34,33 0 0 0,32 0 0 0 0 I35V GTC 754
756:C/T 35 100 99,53 100 97,81 99,06 100 0 I35 silent ATT 756
757:G/A 35,33 0 0 0 0 0,38 0 0 V36M ATG 757
757:G/C 35,33 48,16 0 0 0 0 0 0 V36L CTG 757
759:G/C 36 0 0 0 0,33 0 0 0 V36 silent GTC 759
762:A/G 37 0 0,79 0 0 0 0 0 S37 silent TCA TCG 762
765:T/C 38 100 1,22 0 0 80,64 0 0 T38 silent ACT ACC 765
768:T/C 39 0 1,27 0,79 99,43 0 0 0 A39 silent GCT GCC 768
769:A/G 39,33 100 100 0 94,29 100 99,65 0 T40A GCC 769
771:C/T 40 0 0,49 0 0,42 0 0 0 T40 silent ACT 771
773:A/G 40,67 0 0 0 0 0 0 100 773
774:A/G 41 0 0 1,07 99,86 0 99,87 0 Q41 silent CAA CAG 774
777:C/A 42 0 0,32 0,14 0 0 99,67 0 ACA 777
777:C/G 42 0 0 0 0 0 0,33 0 ACG 777
777:C/T 42 0 99,53 99,65 0,42 98,76 0 0 ACT 777
780:C/T 43 0 1,78 0,71 0,03 1,13 0 0 F43 silent TTC TTT 780
781-783:CTG/TNA 0 0 0 0 0 0 0
781:C/T 43,33 0 1,77 0,59 1,16 37,97 0 0 TTG 781
783:G/A 44 0 0,62 0 0,44 0 0 0 CTA TTA -> L silent 783
786:A/G 45 0 0,43 0 0 0,16 0 0 A45 silent GCA GCG 786
789:G/A 46 0 1,7 0 0 4 0 0 ACA 789
789:G/C 46 0 0,55 0 100 0 100 0 ACC 789
792:C/T 47 0 0,73 0 0 0 0 0 C47 silent TGC TGT 792
795:C/T 48 0 0,64 0 0,78 0 0 0 I48 silent ATC ATT 795
798:T/C 49 0 0,77 0 99,97 0 100 0 N49 silent AAT AAC 798
804:A/G 51 100 100 0 99,97 0 100 0 V51 silent GTA GTG 804
807:C/T 52 0 0 0,39 0 0 0 0 C52 silent TGC TGT 807
813:T/C 54 0 0,37 0 0,83 0,58 0 0 T54 silent ACT ACC 813
816:C/T 55 0 1,29 0 0 0,14 0 0 V55 silent GTC GTT 816
819:C/T 56 0,5 0 0 0 0 0 0 Y56 silent TAC TAT 819
822:C/T 57 100 0 0 0,35 0 0 0 H57 silent CAC CAT 822
825:G/A 58 0 0,35 0,13 0 100 0 0 G58 silent GGG GGA 825
828:C/G 59 0 0 0 0,37 0 0 0 GCG 828
828:C/T 59 99,37 98,92 99,65 0 100 0 0 GCT 828
831:A/G 60 0 0 0 0 0 4,22 0 G60 silent GGA GGG 831
834:G/A 61 0 0 0 100 0 100 0 T61 silent ACG ACA 834
835:A/C 61,33 0 99,64 0 0 0 0 0 R62 silent AGG CGG 835
840:C/T 63 100 0,51 0,27 1,07 0 0 0 T63 silent ACC ACT 840
843:C/T 64 100 8,62 0,33 0,82 2,4 0 0 I64 silent ATC ATT 843
846:A/G 65 0 0 0,29 99,88 77,99 100 0 A65 silent GCA GCG 846
849:A/G 66 0 0,76 0 0,23 0 0 0 S66 silent TCA TCG 849
851:C/T 66,67 0 0,3 0 0 0 0 0 P67L CTC 851
852:C/A 67 0 0 99,23 0 0 0 0 CCA 852
852:C/T 67 0 100 0 0 0 18,69 0 CCT 852
855:G/A 68 0 0,14 0,51 12,99 8,15 0 0 K68 silent AAG AAA 855
858:T/C 69 0 1,84 0,42 0 0 0 0 G69 silent GGT GGC 858
861:T/C 70 0 95,31 0 0 0 0 0 P70 silent CCT CCC 861
862-864:GTC/ANG 0 0 0 0 0 0 0
862-864:GTC/ANT 0,62 0 0 0 0 0 0 V71I ATT
862:G/A 70,33 0,62 0 0 0 0 0 0 ATC 862
864:C/G 71 1,96 0 0 0 0 0 0 GTG 864
864:C/T 71 94,35 99,65 88,15 63,21 100 99,3 0 GTT ATT -> I 864
867:C/T 72 0 7,57 0 0 0 0 0 I72 silent ATC ATT 867
876:T/C 75 28,43 91,76 97,84 28,04 100 100 100 Y75 silent TAT TAC 876
879:C/T 76 0 0,61 0 0 2,38 0 0 T76 silent ACC ACT 879
882:T/C 77 0 54,85 13,25 1,85 0,16 0 0 N77 silent AAT AAC 882
885:G/A 78 0 0 0 72,55 0 99,21 0 V78 silent GTG GTA 885
886:G/C 78,33 0 0,5 0 0 0 0 0 D79H CAC 886
888:C/T 79 0 0,55 0 99,38 0 100 0 D79 silent GAT 888
889-891:CAA/ANG 0 99,6 97,86 0 0 0 0 Q80K AAG
889:C/A 79,33 100 100 99,74 0 100 0 0 Q80K AAA 889
891:A/G 80 0 99,6 97,86 0,42 0 0 0 Q80 silent CAG 891
894:C/T 81 100 0 0,46 0,23 0 0 0 D81 silent GAC GAT 894
897:T/C 82 99,67 1,64 0 100 0,13 99,81 0 L82 silent CTT CTC 897
898-900:GTG/ANA 0 0 0 20,92 0 0 0
898:G/A 82,33 0 0 0 20,92 0 0 0 V83M ATG 898
900:G/A 83 0 0,14 0 99,68 0 99,67 0 V83 silent GTA ATA -> V83I (1 and 3) 900
903:C/G 84 0 1,13 0 0 0 0 0 G84 silent GGC GGG 903
909:C/T 86 0 2,54 0,19 0 0,54 42,58 0 P86 silent CCC CCT 909
910:G/A 86,33 0,45 0 0 0 0 0 0 A87T ACT 910
910:G/T 86,33 5,8 0 0 0 0 0 0 A87S TCT 910
912:T/- 87 0 0 0 2,84 0 0,18 0 GC- 912
912:T/C 87 0 0,4 0,16 97,16 0 99,82 0 A87 silent GCC 912
915:T/C 88 0 1,61 0,67 0,36 0,21 0 0 CCC 915
915:T/G 88 0 0,36 0 0 0 0 0 CCG 915
916-917:CA/TC 0 0 0 20,28 0 97,26 0 Q89S TCA
916:C/T 88,33 0 0 0 20,28 0 100 0 Q89 STOP TAA TCG -> Q89S (1,2 and 3) 916
917:A/C 88,67 0 0 0 98,93 0 97,26 0 Q89P CCA 917
918:A/- 89 0 0 0 1,07 0 0 0 CA- 918
918:A/G 89 0 99,63 0 0 64,62 100 0 Q89 silent CAG 918
921:T/A 90 0 0 100 0 0 0 0 GGA 921
921:T/C 90 0 99,34 0 1,03 0 0 0 GGC 921
921:T/G 90 0 0 0 0 19,66 0 0 GGG 921
924:C/T 91 0 0 0 0 100 0 0 S91 silent TCC TCT 924
927:C/T 92 0 99,49 0 0 0 0 0 R92 silent CGC CGT 927
930:A/G 93 0 1,22 0 0,16 0 0 0 S93 silent TCA TCG 930
931:T/C 93,33 0 10,65 0 1,68 0 0 0 L94 silent CTG 931
933:G/A 94 99,85 0 0 92,07 0,35 99,71 0 L94 silent TTA 933
934:A/G 94,33 0 0,78 0 0 0,14 0 0 T95A GCA 934
936:A/G 95 100 0,93 0 0 0 0 0 T95 silent ACG 936
939:C/T 96 0 0 0 0,2 0,28 0 0 P96 silent CCC CCT 939
942:C/T 97 0 0 0 0,37 0 0 100 C97 silent TGC TGT 942
945:C/T 98 0 2,65 0 97,98 0,55 99,82 0 T98 silent ACC ACT 945
948:C/T 99 0 99,3 0,32 0 1,23 0 0 C99 silent TGC TGT 948
951:C/T 100 0 0,28 0 0 0 0 0 G100 silent GGC GGT 951
954:C/T 101 0 0,54 0,47 0 0 0 0 S101 silent TCC TCT 954
957:G/A 102 9,34 0,67 0 7,76 0 0,38 0 S102 silent TCG TCA 957
960:C/T 103 0 0,35 0,4 0 0 0 0 D103 silent GAC GAT 960
NS2
NS3
CAA
ATC
GTG
ACC
all samples genotype 1a
GTC
T42 silent
clincally relevant mutations 
mutation
plasmid sequence different from reference sequence
Q80
G90 silent
silent mutation
actual mutation
CAA
ACC
GTG
GCT
CCTP88 silent
GGT
ACA
TTG
CCCP67 silent
V71 silent
GAC
CTGL44 silent
T46 silent ACG
GCCA59 silent
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List of variants second deep sequencing run 
 
reference sequence Re.1a.US.77.H77
genotype
number of reads 9926 7804 13019 5001 7921 6690 6498 5904 5264
Variant
aminoacid 
position in 
NS2/3
B05-08 % B49-03 % B51-01 % B84-01 % C01-15 % B35-04 % B37-03 % B57-01 %
WT control 
(H77 plasmid 
DNA from 
Selena) %
variant original codon new codon
Variant
576:C/T 192 98,23 0,78 0 0,55 0 0 98,19 0 0 P192 silent CCC CCT 576
579:C/T 193 0 0 0 0 0 0,1 0 98,46 0 V193 silent GTC GTT 579
582:T/A 194 56,98 0 0 0 0 0 0 0 0 TCA 582
582:T/C 194 37,79 18,98 99,77 99,11 98,97 67,41 96,46 4,74 0 TCC 582
588:T/C 196 100 7,16 0 0,63 0 0 99,56 100 0 R196 silent CGT CGC 588
589:A/C 196,3333333 0 0 0 2,15 0 0 0 0 0 R197 silent CGG 589
590:G/A 196,6666667 100 0 0 0 0 0 52,82 0 0 AAG 590
591:G/A 197 0 0 0 0 0 0 0 99,52 0 AAA 591
594:C/T 198 0 0 72,79 0 0 0,65 0 0 0 G silent GGC GGT 594
596:A/G 198,6666667 90,56 97,58 92,78 89,97 93,83 87,63 94,51 100 0 Q199 R CGG 596
597:G/A 199 0 0 0 0 3,3 0 0 99,63 0 Q199 silent CAA 597
601:A/G 200,3333333 0 0 0 0 0 0 37,02 0 0 I201 V ATA GTA 601
604:C/T 201,3333333 0,18 1 0 100 0 0 3,2 0 0 TTG 604
606:G/A 202 0 6,8 0 0 0 0 0 0 0 CTA 606
609:T/C 203 14,47 95,04 99,26 99,49 100 99,78 99,88 95,77 0 L 203 silent CTT CTC 609
612:G/A 204 0 94,82 95,29 99,14 99,44 67,48 0 100 0 GGA 612
612:G/C 204 0 0 0 0,49 0 0 0 0 0 GGC 612
615:A/G 205 95,85 0,9 0 0,18 0 98,99 0,99 99,6 0 P 205 silent CCA CCG 615
618:C/T 206 0 0 0 0,52 0 0 0 0 0 A 206 silent GCC GCT 618
621:C/T 207 99,56 23,84 100 100 34,1 97,69 100 97,28 0 D207 silent GAC GAT 621
623:G/C 207,6666667 0 0 0 100 0 0 0 0 0 G208 A GCA 623
624:A/C 208 0 0 0 0,62 0 0 0 0 0 GGC 624
624:A/G 208 0 3,68 0 0 0 0 0 0 0 GGG 624
624:A/T 208 0 0 0 92,09 0 0 0 0 0 GGT 624
625:A/G 208,3333333 0 0 0 0 0 0 99,55 0 0 M209 V GTG 625
627:G/A 209 0 0 0 0 0 0 0,67 0 0 M209 I ATA 627
628:G/A 209,3333333 0 0 0 0 2,41 0 0 8,97 0 V210 I ATC V210T =ACC 628
629:T/C 209,6666667 0 0 0 0 100 0 0 100 0 V210 A GCC 629
633:C/T 211 0 6,06 0 0 0 0 0 0 0 S211 silent TCC TCT 633
635:A/G 211,6666667 0 0 0 4,28 0 0 0 0 0 K212 R AAG AGG 635
639:G/A 213 0 0 2,21 0 0,2 0,27 0 0 0 G 213 silent GGG GGA 639
645:G/A 215 0 0 61,23 0 99,83 0 0 0 0 R215 silent AGG AGA 645
646:T/C 215,3333333 0 0 100 85,23 0 0 0 70,51 0 L216 silent TTG CTG 646
649:C/T 216,3333333 0 0 97,99 0 0 0 0 0 0 TTG 649
651:G/A 217 0 0 0 0,4 0 2,54 0 0 0 CTA 651
651:G/T 217 0 0 0 0 0 3,02 0 0 0 CTT 651
654:G/A 1 100 0 0 0 0 30,8 0 0 0 A1 silent GCG GCA 654
657:C/T 2 0 0 0 12,45 0 0,26 0,62 0 0 P2 silent CCC CCT 657
660:C/T 3 0 0 0 0,17 0 0 41,31 0,49 0 I3 silent ATC ATT 660
663:G/A 4 0 0 0 0 0 0 0 97,58 0 ACA 663
663:G/C 4 0 0 0 0 100 0 0 0 0 ACC 663
666:G/A 5 0 0 0 85,21 0 0 0 0 0 A5 silent GCG GCA 666
669:C/T 6 0 0 0 1,23 0 99,82 0,17 0 0 Y6 silent TAC TAT 669
672:C/T 7 0 0 0 0 0 0 0 31,03 0 A7 silent GCC GCT 672
675:G/A 8 0 0 0 0 0 3,29 0 0 0 Q8 silent CAG CAA 675
681:G/A 10 100 0 99,71 5,83 99,59 100 0 97,21 0 T10 silent ACG ACA 681
682:A/C 10,33333333 0 0 0 0 67,5 0 0 0 0 CGA 682
684:A/G 11 100 100 99,85 99,72 99,9 99,64 99,45 100 0 AGG 684
690:C/T 13 0 0 0 0 0 0 0 47,17 0 L13 silent CTC CTT 690
691:C/T 13,33333333 0 0 0,35 8,43 0,34 98,46 0 85,12 0 TTA 691
693:A/G 14 0,16 0 0 100 0,34 99,59 0,86 100 0 CTG 693
696:G/A 15 3,27 0 0 6,48 3,13 99,77 0,64 98,69 0 G15 silent GGG GGA 696
699:T/C 16 99,86 99,78 100 99,75 0,27 100 100 99,58 0 C16 silent TGT TGC 699
703:A/G 17,33333333 0 0 0 0 3,13 0 0 0,34 0 I18V GTC 703
705:C/T 18 0 0 0 0,34 0 46,25 0 99,58 0 I18 silent ATT 705
708:C/G 19 0 0 0 0 0 0 0,99 0 0 T19 silent ACC ACG 708
711:C/T 20 0 0 99,62 0 0 0 0 0 0 S20 silent AGC AGT 711
712:C/T 20,33333333 0 0 1,81 0,45 0 0 0 0 0 TTG 712
714:G/A 21 93,21 0 0 0 35,01 0 99,76 0 0 CTA 714
714:G/T 21 0 0 0 0 0 98,95 0 0 0 CTT 714
717:T/A 22 0 0 0 0 0 0 0 99,76 0 ACA 717
717:T/C 22 0 8,24 0 0,17 0 99,71 100 0 0 ACC 717
720:C/T 23 0 0 32,26 0 0 0 0 0,04 0 G23 silent GGC GGT 720
721:C/A 23,33333333 0 0 64,13 0 0 0 0 0 0 AGG 721
723:G/A 24 0 92,02 99,6 84,15 0 0 0 0 0 CGA 723
723:G/C 24 0 0 0 15,27 0 0 0 0 0 CGC 723
726:C/T 25 0 0 0 0 0 0 13,33 0 0 D25 silent GAC GAT 726
728:A/G 25,66666667 0 0 0,13 0 22,51 0 0 0 0 K26R AGA 728
729:A/G 26 0,47 100 32,57 0,94 0 0 99,72 99,66 0 K26 silent AAG 729
732:C/T 27 0 0,44 0 0 0 0 0 0 0 N27 silent AAC AAT 732
735:A/G 28 0 0 0 0 99,83 0 0 99,48 0 Q28 silent CAA CAG 735
737:T/C 28,66666667 100 0 0 0 0 0 0 0 0 V29A GCG 737
738:G/A 29 0 0 65,16 0 0 0 0 0 0 V29 silent GTA 738
739:G/- 29,33333333 0 0 0,57 0 0,17 0 0 0,34 0 E30 delete GAG AG 739
744:T/A 31 0 0 0 0 2,12 0 0 0 0 GGA 744
744:T/C 31 100 100 0 0,37 0 0 0 1,18 0 GGC 744
747:G/A 32 0 0 0 0 0,42 0 0 0 0 E32 silent GAG GAA 747
750:C/A 33 0 1,24 0 0 0 0 16,01 0,04 0 GTA 750
750:C/T 33 0 4,2 0 1,03 0 0 0,14 99,52 0 GTT 750
753:G/A 34 0 30,45 0 0 0 0 0 0,04 0 Q34 silent CAG CAA 753
756:C/T 35 100 80,8 100 99,83 77,44 99,81 99,88 99,76 0 I35 silent ATC ATT 756
759:G/A 36 99,01 0 0 0 0 0 0 98,64 0 V36 silent GTG GTA 759
765:T/C 38 0 0 0 0 96,34 0,29 0 29,84 0 T38 silent ACT ACC 765
768:T/C 39 0 0 3,4 0,86 0 67,43 0 0 0 A39 silent GCT GCC 768
769:A/G 39,33333333 100 100 100 100 100 38,48 100 100 0 T40A ACC GCC 769
773:A/G 40,66666667 0 0 0 0 0 0 0 0,04 100 Q41R CGA 773
774:A/G 41 94,15 0 0 0 0 99,6 99,83 100 0 Q41 silent CAG 774
777:C/T 42 0 2,28 98,25 98,35 97,39 0 0 0 0 T42 silent ACC ACT 777
780:C/T 43 0 2,98 0 0,15 0 0 0 0,15 0 F43 silent TTC TTT 780
781:C/T 43,33333333 99,66 1,18 0 0 0 0,51 0 0 0 L44 silent CTG TTG 781
786:A/C 45 1,15 0 0 0 0 0 6,59 0 0 GCC 786
786:A/G 45 0 0 97,54 0 0,61 0 0 0 0 GCG 786
786:A/T 45 98,85 0 0 0 0 0 93,41 0 0 GCT 786
789:G/A 46 1,4 0,28 0 0,6 0 0 0 0 0 ACA 789
789:G/C 46 0 0 0 0 0 99,45 0 96,95 0 ACC 789
789:G/T 46 0 0 0 0 0 0,55 0 2,91 0 ACT 789
792:C/T 47 0 0 0 0 0,34 0 0 0 0 C47 silent TGC TGT 792
795:C/T 48 0 61,33 0 0 0 0 0 0 0 I48 silent ATC ATT 795
798:T/C 49 0 99,9 0 0 0 3,97 0 98,91 0 N49 silent AAT AAC 798
801:G/A 50 0 0 0 0,18 0 0 62,45 96,73 0 G50 silent GGG GGA 801
804:A/G 51 100 0 0 100 0 97,58 99,84 100 0 V51 silent GTA GTG 804
805:T/C 51,33333333 100 0 0 0 0 0 0 0 0 805
genotype 1a genotype 1b
GTG
ACGT46 silent
CTCC52L
ACGT4 silent
AGAR11 silent
CTAL14 silent
ATC
CTGL21 silent
ACTT22 silent
CGGR24 silent
AAA
CAA
GCAA45 silent
GGTG31 silent
GTCV33 silent
GGA
ATG
GTC
CTG
TCT
AGG
CAG
CTG
GGG
S194 silent
R197K
L 202 silent
G 204 silent
G 208 silent
L217 silent
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805:T/C 51,33333333 100 0 0 0 0 0 0 0 0 805
806:G/T 51,66666667 100 0 0 0 0 0 0 0 0 806
807:C/T 52 0 0 0 0 0,92 0,51 0 0 0 C52 silent TGT 807
811:A/G 53,33333333 99,97 0 0 0 0 0 0 0 0 T54A GCT 811
813:T/C 54 0 0 99,73 0 99,08 26,67 5,77 0,63 0 T54 silent ACC 813
816:C/T 55 5,2 0 0 0 0,93 0,4 0 0 0 V55 silent GTC GTT 816
822:C/T 57 99,63 14,78 3,51 0 0,73 97,35 0,13 67,41 0 H57 silent CAC CAT 822
825:G/A 58 0,13 0 0 100 0 0 0 0 0 G58 silent GGG GGA 825
828:C/T 59 0 97,08 99,12 100 0,75 66,49 0 2,84 0 A59 silent GCC GCT 828
831:A/G 60 0 0 0 0 0 0 1,68 0 0 G60 silent GGA GGG 831
832:A/T 60,33333333 100 0 0 0 0 0 0 0 0 T61S TCG 832
834:G/A 61 0 0 0 0 0 0 0 99,67 0 T61 silent ACA 834
835:A/C 61,33333333 0 1,4 30,7 0 0 0 0 0 0 R62 silent AGG CGG 835
840:C/T 63 0 0 0 0,31 0 0 99,87 0 0 T63 silent ACC ACT 840
841:A/C 63,33333333 99,77 0 0 0 0 0 0 100 0 I64L CTC 841
843:C/A 64 100 0 0 0 0 0 0 0 0 ATA 843
843:C/T 64 0 2,54 0,3 0 0 1,05 0,87 0 0 ATT 843
846:A/G 65 0 3,86 0 0 100 0 99,63 100 0 A65 silent GCA GCG 846
849:A/G 66 0 1,24 0 0,31 0 0 0 0 0 S66 silent TCA TCG 849
850:C/T 66,33333333 100 0 0 0 0 0 0 0 0 P67S TCC 850
852:C/T 67 0 0 1,41 3,28 0,29 0,9 0 0 0 P67 silent CCT 852
855:G/A 68 0 100 2,01 0 0 0 0 0 0 K68 silent AAG AAA 855
858:T/C 69 0 0 100 0,38 0,17 0 0,94 0 0 G69 silent GGT GGC 858
861:T/C 70 0 94,82 0 0 0 99,04 0 0 0 P70 silent CCT CCC 861
864:C/T 71 98,41 1,24 0 99,65 98,39 98,82 83,74 93,13 0 V71 silent GTC GTT 864
870:G/A 73 0 0 100 0 0 0 0 0 0 Q73 silent CAG CAA 870
876:T/C 75 0,32 9,32 1,05 99,74 100 0 36,45 2,28 100 Y75 silent TAT TAC 876
882:T/C 77 0 0 0 0 94,77 2,97 0 0,39 0 N77 silent AAT AAC 882
885:G/A 78 99,31 0 0 0 0 99,85 99,47 100 0 V78 silent GTG GTA 885
889:C/A 79,33333333 100 100 100 100 100 0 100 0 0 Q80K AAA AGG -> R (all 3) 889
890:A/G 79,66666667 0 0 0 15,56 0 0 0,46 0 0 Q80R CGA AAG -> K (1 and 3) 890
891:A/G 80 3,78 100 100 100 1,1 0 0,66 0 0 Q80 silent CAG 891
894:C/T 81 0 0 0 0 0 0 1,43 0 0 D81 silent GAC GAT 894
897:T/C 82 0 0 0 100 4,38 100 0,12 95,7 0 L82 silent CTT CTC 897
898:G/A 82,33333333 0 0 0 0 0 0 0 100 0 V83M ATG ATA -> I (V83I) 898
900:G/A 83 0 0 0 0 65,1 68,8 0,61 100 0 V83 silent GTA 900
903:C/T 84 0 1,06 30,6 0 6,14 0 62,57 0 0 G84 silent GGC GGT 903
907:C/G 85,33333333 100 0 0 0 0 0 0 0 0 P86A GCC 907
907:C/T 85,33333333 0 0 1,05 0 0 0 0 0 0 P86S TCC 907
909:C/T 86 0 0 0 0,17 34,63 0 0 0 0 P86 silent CCT 909
911:C/- 86,66666667 0 0 0 0 0 0 0 0,33 0 G-C 911
912:T/C 87 0 0 0 0,35 0 0 0 0 0 A87 silent GCC 912
913:C/T 87,33333333 0 0 0 0 0 0 0 0,52 0 P88S TCT 913
915:T/C 88 0,16 17,22 0 0 0 100 0,18 98,95 0 P88 silent CCC 915
917-920:AAGG/---- #WERT! 0 0 0 0 0 0 0 0,52 0 917-920:AAGG/----
917:A/C 88,66666667 100 0 0 0 0 0 0 0 0 Q89P CCA 917
918:A/G 89 0 99,38 0 0 0 0 99,56 69,86 0 Q89 silent CAG 918
921:T/A 90 0 0 0 2,59 2,34 0 0 0 0 GGA 921
921:T/C 90 100 0 0 0,68 6,58 0,4 0 0 0 GGC 921
922:T/A 90,33333333 100 0 0 0 99,69 0 0 0 0 S91T ACC 922
922:T/G 90,33333333 0 0 0 0 0,1 100 0 100 0 S91A GCC 922
923:C/G 90,66666667 0 0 0 0 5,79 0 0 0 0 S91C TGC 923
924:C/A 91 0 0 0 0 0 0 0 2,36 0 TCA AGC -> S (1 and 2) 924
924:C/T 91 0 16,94 0 0,14 0 0 3,09 61,51 0 TCT 924
927:C/T 92 0 0 0 99,52 0 0 0 0 0 R92 silent CGC CGT 927
930:A/G 93 0,18 0 0 99,86 0 0 0,83 0 0 S93 silent TCA TCG 930
931:T/C 93,33333333 55,93 0 0 2,91 3,65 3,01 37,59 94,55 0 L94 silent CTG 931
933:G/A 94 0 0 98,72 0 0 0 0 100 0 L94 silent TTA 933
934:A/G 94,33333333 0 1,04 0 0 0 0 0,53 0 0 T95A GCA 934
935:C/T 94,66666667 0 0 0 0 0 0 0 96,15 0 T95I ATA 935
936:A/G 95 100 0 0 0 0 0 0,46 100 0 T95 silent ACG ATG -> M (2 and 3) 936
939:C/A 96 0 0 0 0 99,58 0 0 0 0 CCA 939
939:C/G 96 0 0 0 0 0,42 0 0 0 0 CCG 939
939:C/T 96 0 0 0 0 0 0 0,55 1,99 0 CCT 939
942:C/T 97 0 0 0 0 0 0 0 0 100 C97 silent TGC TGT 942
945:C/G 98 0 0 0 0 0 0,4 0 0 0 ACG 945
945:C/T 98 0 0 2,92 100 0 66,98 0 0 0 ACT 945
948:C/T 99 97,53 99,74 0 7,39 0 0 0 0 0 C99 silent TGC TGT 948
951:C/T 100 0 75,96 0 0 0 0 0 0 0 G100 silent GGC GGT 951
952:T/A 100,3333333 0 0 0 1,68 0 0 0 0 0 S101T ACC 952
954:C/T 101 0 0 2,52 0 0 0 0 50,56 0 S101 silent TCT 954
957:G/A 102 99,72 0 0 0 0 99,6 0 0,61 0 TCA 957
957:G/C 102 0 0 0 97,12 0 0 0 0 0 TCC 957
957:G/T 102 0 0 0 0,28 0 0 0 0 0 TCT 957
NS2
NS3
genotype 1bgenotype 1a
TCC
TCGS102 silent
CCC
GTG
CCC
ACA
CCCP96 silent
CTCC52L
ACG
ATCI64 silent
TGC
ACT
TCC
TTG
silent mutation
actual mutation
ACCT98 silent
CAA
GCT
CCT
CAA
GGT
Q80
plasma sequence different from reference sequence
clinically relevant mutation
mutation
G90 silent
S91 silent
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List of variants third deep sequencing run
 
reference sequence Re.1a.US.77.H77
genotype
Number of reads 6385 7477 5359 4300 5750 3848 4455 3759 5514
Variant
aminoacid 
position in 
NS5b
A42-10 % A57-10 % A85-03 % A76-05 % B35-04 % B37-03 % B57-01 % C06-01 %
WT control (IT 
H77 RNA from 
Selena) combined 
%
variant original codon new codon Variant
678.5:-/T 0 0 0 0 0 0 0 100 0 678.5:-/T
691-693:AGC/GAG 0 0 0 0 0 0 0 0 0 S231E GAG 691-693:AGC/GAG
691-693:AGC/GAT 0 0 0 0 0 0 0 0 0 S231D GAT 691-693:AGC/GAT
691-693:AGC/GCG 0 0 0 0 0 0 0 0 0 GCG 691-693:AGC/GCG
691-693:AGC/GCT 0 0 0 0 0 0 0 0 0 GCT 691-693:AGC/GCT
691:A/G 230,333333 0 0 0 0 0 95,71 0 0 0 S231G GGC 691
692:G/A 230,666667 0,55 0 0 0,33 0 2,88 0,29 99,57 0 S231N AAC 692
692:G/C 230,666667 0 0 0 0 0 5,38 0 0 0 S231T ACC 692
693:C/G 231 0 0 0 0 0 0 0 99,63 0 S231R AGG 693
693:C/T 231 0 0 14,54 0,63 0 2,88 0,29 0 0 S231 silent AGT 693
696:C/T 232 1,03 2,65 0 0,58 99,81 96,91 99,71 1,17 0 D232 silent GAC GAT 696
703-705:ACG/GTT 0 0 0 0 0 2,88 0,16 0 0 T235V GTT 703-705:ACG/GTT
703:A/G 234,333333 0 0 0 0 0 2,88 0,16 0 0 T235A GCG 703
704:C/T 234,666667 0 0 0 0 0 2,88 0,29 100 0 T235M ATG 704
705:G/T 235 0 0 0 0 0 2,88 0,29 0 0 T235 silent ACT 705
712:G/A 237,333333 0 0 0 8,65 0 0 0 0 0 A238T ACA 712
712:G/T 237,333333 0 0 0 0 0 2,88 0,29 0 0 A238S TCA 712
717:T/C 239 99,22 97,87 100 100 99,84 100 0,29 97,69 0 I239 silent ATT ATC 717
723:A/G 241 0 0 98,25 100 38,71 0,21 99,19 0 0 Q241 silent CAA CAG 723
733:C/T 244,333333 0,7 0,47 100 0,4 0 2,88 0,29 0 0 L245 silent CTG TTG 733
737:A/C 245,666667 0 0 0 0 0 2,88 0,16 0 0 D246A GAC GCC 737
741:C/T 247 0 99,09 0 0 0 0 0 99,52 0 P247 silent CCC CCT 741
742-744:CAA/GNG 0 0 0 0 0 0 0 0 0 GAG 742-744:CAA/GNG
742:C/G 247,333333 0 0 100 0 0 2,88 0,29 0 0 GAA 742
744:A/G 248 99,08 99,77 0 0,12 0,19 97,12 0 100 0 Q248 silent CAG 744
745.5:-/G 0,49 0 0 0 0 0 0 0 0 745.5:-/G
748-750:CGC/ANA 0 0 0 0 0 2,88 0,29 0 0 R250 silent AGA 748-750:CGC/ANA
748-750:CGC/ANT 0 0 0 0 0 0 0 0 0 AGT 748-750:CGC/ANT
748:C/A 249,333333 0 0 0 0 0 2,88 0,29 0 0 AGC 748
750:C/A 250 0 0 0 0,12 0,19 3,3 0,29 0 0 CGA 750
750:C/T 250 1,05 8,88 0 0,72 0,75 0,6 2,9 0,85 0 CGT 750
751-752:GT/CA 0 0 0 0 0 2,88 0,16 0 0 V251Q CAG 751-752:GT/CA
751:G/C 250,333333 0 0 0 0 0 2,88 0,16 0 0 V251L CTG 751
752:T/A 250,666667 0 0 0 0 0 2,88 0,29 0 0 V251E GAG 752
755-756:CC/TT 0 0 0 0 0 0 0 0 0 GTT 755-756:CC/TT
755:C/T 251,666667 0 0 0 0,93 0 0 0 0 0 GTC 755
756:C/T 252 0 0 0,11 0 0 0 27,03 0 0 A252 silent GCT 756
759:C/A 253 0 0 0 0 0 2,88 0,29 0 0 ATA 759
759:C/T 253 0,56 0 0 0,12 0,5 0,42 0,72 0,4 0 ATT 759
761-762:AG/CA 0 0 0 0 0 0 0 100 0 K254T ACA 761-762:AG/CA
761-762:AG/GA 0 0 0 0 0 0 0 0 0 K254R AGA 761-762:AG/GA
761:A/C 253,666667 0 0 0 0 0 0 0 100 0 K254Q CAG 761
761:A/G 253,666667 0 0 0 0 0 2,88 0,16 0 0 K254R AGG 761
762:G/A 254 0 0 0 0 0 0 0 100 0 K254 silent AAA 762
765:C/A 255 0 0 0 0 60,05 0 0 0 0 TCA 765
765:C/G 255 0 0 0 0 0,24 2,88 0,29 0 0 TCG 765
765:C/T 255 0 1,2 100 99,88 0 0 0 0 0 TCG 765
768:C/T 256 0 0 0 70,19 0 0 0 0 0 L256 silent CTC CTT 768
771:T/A 257 0 0 0 0,35 0 2,88 0,29 0 0 ACA 771
771:T/C 257 0,41 0 99,76 98,28 99,5 96,96 98,97 0,51 0 ACC 771
775:A/C 258,333333 0 0 0 0 0 2,88 0,16 0 0 R259 silent AGG CGG 775
780:T/G 260 0 1,06 0 0 0 0 0 0 0 L260 silent CTT CTG 780
783:T/C 261 0 0,47 0,9 0 0 2,88 0,16 0 0 Y261 silent TAT TAC 783
784-786:GTT/ANC 0 0 0 0 0 2,88 0,29 0 0 ATC 784-786:GTT/ANC
784:G/A 261,333333 0 0 0 0 0 2,88 0,29 0 0 ATT 784
786:T/C 262 0 0 90,71 98,65 98,9 4,08 92,62 0,21 0 V261 silent GTC 786
792:C/T 264 0 0 0 0 0,42 0 0 100 0 G264 silent GGC GGT 792
795:T/C 265 0,53 0 0 0 0 2,88 0,16 1,04 0 P265 silent CCT CCC 795
798:T/C 266 0,78 0 0 0,28 0 0 99,42 0 0 CTC 798
798:T/G 266 0 0 0 0 0 2,88 0,16 0 0 CTG 798
801:C/T 267 0 0 0 0,16 0 2,88 0,29 0 0 T267 silent ACC ACT 801
804:T/C 268 0,47 0 6,1 0 0 0 68,91 0 0 N268 silent AAT AAC 804
807:A/T 269 0 0 0 0 0 2,88 0,16 0 0 S269 silent TCA TCT 807
808.5:-/A 1,61 0 0 0 0 0,21 0,85 0 0 808.5:-/A
809-810:GG/AA 0,56 0 0 0 0 2,88 0,29 0 0 AAA 809-810:GG/AA
809:G/A 269,666667 92,34 0 0 0,12 96,07 3,3 57,62 0 0 AAG 809
810:G/A 270 1,11 0 0 0 0 2,88 0,29 0,69 0 R270 silent AGA 810
814-816:GAA/CNG 0 0 0 0 0 2,88 0,16 0 0 CAG 814-816:GAA/CNG
814:G/C 271,333333 0 0 0 0 0 2,88 0,16 0 0 CAA 814
816:A/G 272 99,3 87,87 0 0,67 3,9 100 0,29 99,49 0 E272 silent GAG 816
822:C/T 274 0,27 0 0 99,77 2,1 0 0 0 0 C274 silent TGC TGT 822
828:C/T 276 1,19 100 99,89 100 67,86 3,3 99,12 75,92 0 Y276 silent TAC TAT 828
832-834:AGG/CNA 0 0 0 0 0 0 0 0 0 CGA 832-834:AGG/CNA
832:A/C 277,333333 0 0 0 0 0 2,88 0,16 0 0 CGG 832
834:G/A 278 0,42 0 4,72 0 0,78 96,73 99,57 1,46 0 AGA 834
840:C/T 280 0 99,63 0 0 0 0 0 0 0 R280 silent CGC CGT 840
843:G/A 281 0,33 0,41 0,9 99,12 0 0 0,38 82,42 0 A281 silent GCG GCA 843
849:C/T 283 0 0 0 0 0 2,88 0,29 0 0 G283 silent GGC GGT 849
852:A/G 284 0 0 0 0,42 0,78 0 0,13 0,29 0 V284 silent GTA GTG 852
858:A/G 286 0,39 87,19 0,65 0,26 100 3,09 100 0 0 T286 silent ACA ACG 858
861:T/C 287 0 0 13,25 0 0 3,01 0,16 0 0 T287 silent ACT ACC 861
867:T/C 289 0 0 100 99,88 0 2,88 0,61 0,51 0 C289 silent TGT TGC 867
870:T/A 290 0 0 98,77 0 0 0 0 0 0 GGA 870
870:T/C 290 0 0,55 0 99,56 0,35 0,36 0 0 0 GGC 870
870:T/G 290 0 0 1,23 0 0 0 0 0 0 GGG 870
873:C/T 291 0,89 0 0,26 0,49 0 3,04 0,29 0 0 N291 silent AAC AAT 873
882:T/A 294 0 0 0 0 0 2,88 0,29 0,13 0 ACA 882
882:T/C 294 0 0 0 0,28 0 0 0 99,6 0 ACC 882
885:C/T 295 0 0 0 0 0 3,17 0,29 0 0 C295 silent TGC TGT 885
888:C/T 296 0 0 0 0 0,78 0 0 0 0 Y296 silent TAC TAT 888
889-891:ATC/TNG 0 0 0 0 0 2,88 0,16 0 0 I297L TTG 889-891:ATC/TNG
889-891:ATC/TNT 0 0 0 0 0 0 0 0 0 TTT 889-891:ATC/TNT
889:A/T 296,333333 0 0 0 0 0 2,88 0,16 0 0 TTC 889
891:C/G 297 0 0 0 0 0 2,88 0,29 0 0 I297M ATG 891
891:C/T 297 0 0 94,51 0,44 0 0,34 0 0 0 I297 silent ATT 891
894:G/A 298 95,58 0 0 0 0 0 0 0 0 K298 silent AAG AAA 894
897:C/T 299 0,31 0 0 0 0 0 0 0 0 A299 silent GCC GCT 897
898-900:CGG/AAA 99,66 0 0 0 0 0 0 99,63 0 R300K AAA 898-900:CGG/AAA
898-900:CGG/AAC 0 0 0 0 0 0 0 0 0 R300N AAC 898-900:CGG/AAC
898-900:CGG/ACC 0 0 0 0 0 0 0 0 0 R300T ACC 898-900:CGG/ACC
898-900:CGG/GAA 0 0 0 0 0 0 0 0 0 R300E GAA 898-900:CGG/GAA
898-900:CGG/GCA 0 0 0 0 0 0 0 0 0 GCA 898-900:CGG/GCA
898-900:CGG/GCC 0 0 0 0 0 0 0 0 0 GCC 898-900:CGG/GCC
898:C/A 299,333333 100 0 0 0 0 0 0 100 0 R300 silent AGG 898
898:C/G 299,333333 0 0 0 0 0 2,88 0,29 0 0 R300G GGG 898
899:G/A 299,666667 100 99,13 100 99,88 99,6 96,91 0 100 0 R300Q CAG 899
genotype 1a genotype 1b
V262I
R270K
E272Q
S231A
A252V
I253 silent
S255 silent
T257 silent
L266 silent
G290 silent
T294 silent
I297F
R300A
R278 silent
ACG
CAAQ248E
CGCR250S
R250 silent
AGC
GAA
AGG
GGT
ACT
ATC
CGG
GTT
CTT
AGG
GCA
ATC
GTG
GCC
AAG
TCC
ACT
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899:G/C 299,666667 0 0 0 0 0 2,88 0,16 0 0 R300P CCG 899
900:G/A 300 99,66 100 100 100 99,79 90,93 97,28 99,63 0 CGA 900
900:G/C 300 0 0 0 0 0 0 2,56 0 0 CGC 900
900:G/T 300 0 0 0 0 0 2,88 0,16 0 0 CGT 900
903:A/G 301 0,64 0 0 0 0 3,01 0,16 0 0 A301 silent GCA GCG 903
915:C/T 305 0 0 0 0 0 2,88 0,29 0 0 A305 silent GCC GCT 915
916-918:GCA/TNG 0 0 0 0 0 0 0 0 0 TCG 916-918:GCA/TNG
916:G/T 305,333333 0 0 31,01 0 0 0 0 0 0 TCA 916
918:A/G 306 97,7 0 0 0,35 0 2,88 0,16 23,33 0 A306 silent GCG 918
919-921:GGG/AAA 0 0 0 0 0 0 0 0 0 G307K AAA 919-921:GGG/AAA
919:G/A 306,333333 0 0 0 0 0 2,88 0,29 0 0 G307R AGG 919
920:G/A 306,666667 0 0 0 0 0 2,88 0,29 0 0 G307E GAG 920
921:G/A 307 0 0 0 17,16 0 0 0 0 0 G307 silent GGA 921
926:A/G 308,666667 0 0 100 99,88 39,39 0 98,27 0 0 Q309R CAG CGG 926
936:C/G 312 0 0 0 0 0 2,88 0,29 0 0 ACG 936
936:C/T 312 0,36 0 0 0 0 0 0 0 0 ACT 936
944:T/C 314,666667 0 0 0 0 0 0 0 0,29 0 V315A GCG 944
945:G/A 315 0 0 0 0 0 2,88 0,29 0 0 V315 silent GTA 945
946-948:TGT/AAC 0 0 0 0 0 1,2 0 0 0 C316N AAC 946-948:TGT/AAC
946:T/A 315,333333 0 0 0 0 0 1,2 0 0 0 C316S AGT 946
947:G/A 315,666667 0 0 0 0 0 1,2 0 0 0 C316Y TAT 947
948:T/C 316 0,66 0 0 0 0 2,88 0,16 0,88 0 C316 silent TGC 948
951:C/A 317 0 0 0 0 0 2,88 0,29 0 0 G317 silent GGC GGA 951
954:C/T 318 1,06 0 0 0 0 0 0 1,68 0 D318 silent GAC GAT 954
958-960:TTA/CNG 0 0 0 0 0 0 0 0 0 L320 silent CTG 958-960:TTA/CNG
958-960:TTA/CNT 0 0 0 0 0 2,88 0,16 0 0 L320 silent CTT 958-960:TTA/CNT
958:T/C 319,333333 98,89 100 0 0 0 2,88 0,76 0 0 L320 silent CTA 958
960:A/G 320 0 0 0 0,84 3,37 6,21 0 0 0 L320 silent TTG 960
960:A/T 320 0 0 0 0 0 2,88 0,16 0 0 L320F TTT 960
967-969:ATC/GNT 0 0 0 0 0 0 0 0 0 GTT 967-969:ATC/GNT
967:A/G 322,333333 0 0 0 0,49 0 0 0 0 0 GTC 967
969:C/T 323 0 0,68 0 0 0 0 0,18 0 0 I323 silent ATT 969
972:T/C 324 0,34 0 0 0 0 0 0 0 0 C324 silent TGT TGC 972
975:A/G 325 99,45 100 0 1,21 0,52 0,21 0 99,41 0 E325 silent GAA GAG 975
978-980:TGC/CCA 0 0 0,58 0,93 40,8 0 0 0 0 978-980:TGC/CCA
978:T/C 326 0,89 0,4 0,58 0,93 41,22 3,25 0,16 97,87 0 978
979-980:GC/CA 0 0 100 98,77 99,39 0 99,71 0 0 979-980:GC/CA
979:G/C 326,333333 0 0 100 98,77 99,39 0 99,71 0 0 979
980:C/A 326,666667 0 0 100 99,88 99,81 0 99,71 0 0 980
981:G/A 327 0 0 1,06 0 0 0 0 0 0 981
984:G/A 328 0 0 99,46 0,12 99,81 0,42 96,18 0 0 G328 silent GGG GGA 984
985-987:GTC/ACT 0 0 0 0 0 0 0 0 0 V329T ACT 985-987:GTC/ACT
985:G/A 328,333333 0 0 0 0 0 2,88 0,29 0 0 V329I ATC 985
986:T/C 328,666667 0 0 0 0 0 2,88 0,16 0 0 V329A GCC 986
987:C/T 329 0 0 0 0 0 95,53 0 0 0 V329 silent GTT 987
989-990:AG/CA 0 0 0 0 0 0 0 0 0 CCA 989-990:AG/CA
989-990:AG/CC 0 0 0 0 0 0 0 0 0 CCC 989-990:AG/CC
989-990:AG/CT 0 0 0 0 0 0 0 0 0 CCT 989-990:AG/CT
989:A/C 329,666667 0 0 0 0 1,86 0 0 0 0 CCG 989
990:G/A 330 0 0 0 0 0 2,88 0,29 0 0 Q330 silent CAA 990
990:G/C 330 0 0 0 0 0 0,57 0 0 0 CAC 990
990:G/T 330 0 0 0 0 0 96,34 0 0 0 CAT 990
993:G/A 331 0 0 0,54 0 0 0 0 0 0 E331 silent GAG GAA 993
996:C/T 332 0,33 0 0,41 0,81 90,19 0 98,95 0 0 D332 silent GAC GAT 996
998-999:CG/AA 0 0 0 0 0 0 0 0 0 A333E GAA 998-999:CG/AA
998-999:CG/TA 0 0 0 0 0 0 0 0 0 A333V GTA 998-999:CG/TA
998:C/A 332,666667 0 0 0 0 0 2,88 0,29 0 0 A333E GAG 998
998:C/T 332,666667 98,65 0 0 0 0 0 0 0 0 A333V GTG 998
999:G/A 333 0 0 0 98,79 93,74 0 99,21 0 0 A333 silent GCA 999
1002:G/A 334 0 0 0 0,28 0 0 0 0 0 A334 silent GCG GCA 1002
1003:A/G 334,333333 0 0 0 0,28 0 0 0 0 0 S335G GGC 1003
1004:G/A 334,666667 0 0 0 0 0 0 0,52 0 0 S335N AAC 1004
1008:G/A 336 0 0 0 0 0 2,88 0,29 0 0 L336 silent CTG CTA 1008
1009-1011:AGA/CNG 0 0 0 0 0 2,88 0,16 0 0 CGG 1009-1011:AGA/CNG
1009:A/C 336,333333 100 100 100 99,88 0 2,88 99,87 100 0 CGA 1009
1011:A/G 337 0 0 0 0 0 2,88 0,16 0 0 AGG 1011
1014:C/T 338 0 0 63,33 0 0 0 0 0 0 A338 silent GCC GCT 1014
1020:G/A 340 0,33 0 0 0 0 0 0 0 0 T340 silent ACG ACA 1020
1026:T/C 342 0,36 0 0 0 0 0 0 0 0 A342 silent GCT GCC 1026
1032:C/T 344 0 0 0 0 0 2,88 0,16 0 0 T344 silent ACC ACT 1032
1035:G/A 345 0 0 0 0 0,78 3,12 0,16 0 0 R345 silent AGG AGA 1035
1038:C/T 346 87,39 0 84,61 0,49 0,31 52,62 98,97 0 0 Y346 silent TAC TAT 1038
1041.5:-/C 0,69 0 0,17 0,21 0 0 2,07 0,13 0 1041.5:-/C
1041:C/T 347 0 0 0 1,4 0 3,04 0,16 0,19 0 S347 silent TCC TCT 1041
1042:G/C 347,333333 2,85 0 0 0 0 0 0 0 0 A348P CCC 1042
1043.5:-/T 0 0 3,41 1,86 0 0 7 0 0 1043.5:-/T
1043:C/G 347,666667 2,85 0 0 0 0 0 0 0 0 A348G GGC 1043
1044.5:-/T 0 0 1,72 2,81 0,5 0 0,4 0 0 1044.5:-/T
1044:C/T 348 0 0 88,39 92,81 99,17 0 90,98 0 0 A348 silent GCT 1044
1045:C/T 348,333333 0 0 0,6 2,09 0 0 0,58 0 0 P349S CCC TCC 1045
1050.5:-/T 0 2,09 0 0 8,47 0 0,22 0 0 1050.5:-/T
1050:C/- 87,3 12,48 49,73 41,95 0,24 96,36 1,23 97,63 80,58 1050:C/-
1050:C/G 350 0 0 0 0 0 0,13 1,28 0 0 CCG 1050
1050:C/T 350 0,42 82,41 0 0,12 89,51 3,51 12,95 0,45 0 CCT 1050
1056.5:-/G 352,166667 0 0 0 0 0 0 1,55 0 0 1056,5
1056:C/T 352 0 0 12,99 0 0 0 0 0 0 D352 silent GAC GAT 1056
1057-1059:CCC/GNG 0 0 0 0 0 0 0 0 0 GCG 1057-1059:CCC/GNG
1057-1059:CCC/GNT 0 0 0 0 0 0 0 0 0 GCT 1057-1059:CCC/GNT
1057:C/G 352,333333 0 0 0 0 0 0 32,35 0 0 GCC 1057
1059:C/G 353 0 0 0 0 0 2,75 0,16 0 0 CCG 1059
1059:C/T 353 0 0 3,28 0 0 0 0 0,43 0 CCT 1059
1061:C/- 57,04 7,38 0,26 0 0 26,33 0,18 56,66 57,44 1061:C/-
1062-1063:AC/-- 0 0 29,02 34,49 0,12 0 10,71 0 0 1062-1063:AC/--
1062:A/- 354 0 0 62,38 67,84 56,19 0 46,87 0 0 1062
1062:A/C 354 0 0 30,29 24,07 38,21 5,35 52,3 0 0 CCC 1062
1062:A/G 354 0 0 0 0,33 0,19 0,21 0,13 0 0 CCG 1062
1062:A/T 354 0 0 0,13 0,23 5,41 0 0,54 0 0 CCT 1062
1063-1064:CA/-- 0 0 6,74 6,3 0 0 0 0 0 1063-1064:CA/--
1063-1065:CAA/ANG 0 0 0 0 0 0 0 0 0 Q355K AAG 1063-1065:CAA/ANG
1063:C/- 354,333333 0 0 35,96 41 0,12 1,51 10,86 0 0 1063
1063:C/A 354,333333 0 0 0 0 0 1,38 0 0 0 Q355K AAA 1063
1065:A/G 355 0 0 31,39 17,51 0 0 0,36 0 0 Q355 silent CAG 1065
1068:A/G 356 0 0 0 0,51 0 0 0 0 0 P356 silent CCA CCG 1068
1071:A/G 357 99,79 98,65 1,18 0,74 0 0 0,4 90,02 0 E357 silent GAA GAG 1071
Var_175 0 0 0 0 0 0 0 0 0 Var_175
Var_176 0 0 0 0 0 0 0 0 0 Var_176
genotype 1a genotype 1b
Q330P
R300 silent
Q330H
R337 silent
I323V
A306S
T312 silent
CCC
CCA
CAA
P350 silent
P353 silent
P354 silent
P353A
GCG
AGC
AGA
GCC
CCC
ATC
GTC
CAG
TGT
TTA
GCA
GGG
ACC
GTG
C316
plasmid sequence different from reference sequence
clincally relevant mutations 
mutation
silent mutation
actual mutation
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Bioanalyzer electropherograms 
 
Mutant Mix 5 ng/µl Mutant Mix 0.5 ng/µl 
Mutant Mix 50 pg/µl Mutant Mix 5 pg/µl 
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Mutant Mix 0.5 pg/µl Mutant Mix WT control 
Mutant Mix 5 ng/µl QCPCR Mutant Mix 0.5 ng/µl QCPCR 
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Mutant Mix WT control QCPCR 
Mutant Mix 50 pg/µl QCPCR Mutant Mix 5 pg/µl QCPCR 
Mutant Mix 0.5 pg/µl QCPCR 
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